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Regolazione microRNA–dipendente dell’espressione genica nella mucosa 
intestinale del paziente celiaco 
 
 Premesse scientifiche 
La celiachia 
La celiachia (CD) è una patologia infiammatoria che si sviluppa in soggetti 
geneticamente predisposti, caratterizzata da una risposta immunitaria indotta 
dall'ingestione di glutine. La prevalenza stimata della CD è circa 1% nella 
popolazione Europea ed Americana; in particolare, in Italia è di 0.55%1,2.  
La presenza del glutine nella dieta dei celiaci, determina una lesione a livello della 
mucosa duodeno-digiunale caratterizzata da atrofia dei villi intestinali, iperplasia delle 
cripte ed incremento dell’infiltrato linfocitario. 
La diagnosi di CD, secondo i criteri ESPGHAN (European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition), si basa sulla dimostrazione di una 
chiara alterazione istologica della mucosa del piccolo intestino mediante biopsia; a 
rafforzare la diagnosi, in presenza di tale specifico quadro istologico, si valuta la 
storia e la presentazione clinica compatibile, la presenza nel siero degli auto-
anticorpi IgA anti-gliadina (AGA), e/o anti-endomisio (EMA) e/o antitransglutaminasi 
(tTG) al momento della diagnosi, la loro normalizzazione, parallelamente alla risposta 
clinica, quando viene intrapresa dieta senza glutine e la genetica compatibile (alleli 
HLA tipici della malattia). La sintomatologia clinica tipica prevede diarrea, dolori 
addominali, vomito e significativa perdita di peso. Tuttavia possono esserci anche 
forme atipiche, silenti e latenti, più difficili da diagnosticare: le forme atipiche sono 
caratterizzate da una compresenza di sintomi extraintestinali (anemia sideropenica, 
osteoporosi, dermatite erpetiforme, bassa statura, anoressia, comparsa recidiva di 
afte, alterazioni dello smalto dentale, stipsi, alopecia); quelle silenti presentano le 
lesioni tipiche della mucosa intestinale in assenza di un’evidente sintomatologia 
clinica; infine, le forme latenti sono caratterizzate da una sierologia positiva per CD, 
ma da negatività alla biopsia intestinale. La CD è un’enteropatia multifattoriale in cui 
il largo spettro di alterazioni cliniche, istologiche e sierologiche osservate nei 
differenti stadi e nelle diverse forme della malattia è spiegato dai fattori genetici ed 
ambientali. Studi di popolazione hanno dimostrato una concordanza tra gemelli 
monozigoti del 75%, mentre tra gemelli dizigoti e parenti di I grado è rispettivamente 
del 20% e 10%3. Ciò indica che esiste una forte componente genetica alla base di 
questa patologia. Ad oggi, la più forte associazione alla celiachia è data dai geni del 
sistema HLA di classe II, codificanti per gli eterodimeri DQ2 e DQ84. E’ stato 
dimostrato un aumento nella frequenza delle molecole DQ2/8 nelle donne (94%) 
rispetto agli uomini (85%) affetti da celiachia (p=1.6 x 10−3) in Italia5. Inoltre, circa il 
90-95% dei celiaci esprime l’eterodimero DQ2, mentre il restante 5-10% 
l’eterodimero DQ84; bisogna considerare però, che circa 1% dei celiaci non possiede 
né il DQ2, né il DQ8, così come esse sono presenti anche nel 35% della popolazione 
sana; ciò fa intendere che la presenza delle molecole DQ2/8 è una condizione 
necessaria ma non sufficiente per sviluppare la malattia e quindi ci sono altri fattori 
che contribuiscono all’insorgere della CD; in tal senso il test genetico di tipizzazione 
HLA per la ricerca degli aplotipi DQ2/DQ8, ha un alto valore predittivo negativo, 
fornendo così un valido supporto sia nello screening dei gruppi a rischio (i.e. familiari 
di primo grado di celiaci), sia nei casi dubbi (i.e. forme latenti). I loci HLA sono parte 
del complesso MHC (Complesso Maggiore di Istocompatibilità), che mappa sul 
braccio corto del cromosoma 6 ed è un sistema altamente polimorfico e complesso. 
Le molecole HLA di classe II, comprendono i geni DR, DQ e DP, sono espresse a 
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livello di cellule immunocompetenti (APC o Antigen Presenting Cell) e cioè 
macrofagi, cellule dendritiche (DCs) e linfociti B e T; la loro funzione è quella di 
legare patogeni extracellulari o parte di essi e presentarli ai linfociti T helper CD4+ 
attivandoli ed innescando così la risposta immunitaria. In particolare, il fattore 
ambientale in grado di suscitare la risposta immunitaria adattativa ed innata nel 
piccolo intestino è rappresentato dalla gliadina, una frazione proteica del glutine, che 
nel tratto gastrico viene deaminata dall’enzima tTG e trasformata in peptidi ricchi di 
acido glutammico ad alta affinità per le molecole DQ2. Tra i peptidi gliadinici 
identificati, sono presenti il peptide 31-43 mer, in grado di attivare l’immunità innata, 
ed il peptide 33mer capace di scatenare la risposta adattativa. Infatti, l’attivazione di 
cellule T glutine specifiche, determina produzione di anticorpi da parte dei linfociti B 
sia per la gliadina che per la tTG; quest’ultimi attivano una reazione immunitaria 
distruttiva sia verso la mucosa intestinale (con infiammazione, iperplasia delle cripte 
e atrofia dei villi), sia verso altri tessuti in cui è espressa la tTG come sistema 
nervoso, cute, denti, fegato e pancreas. In particolare, la risposta immunitaria innata 
è caratterizzata dalla produzione di interleuchina-15 da parte delle cellule 
dendritiche epiteliali e della lamina propria, che aumenta la permeabilità intestinale 
ed induce l’apoptosi degli enterociti dopo la riprogrammazione dei linfociti 
intraepiteliali in natural killer (NK); la risposta adattativa, guida anche una risposta 
pro infiammatoria, caratterizzata soprattutto dalla produzione di interferone-gamma 
(IFNγ), che si conclude nell’enteropatia immuno-mediata. Oltre al locus HLA, 
numerosi studi di associazione genica hanno permesso di identificare 13 loci non-
HLA, in cui sono stati individuati geni coinvolti nella risposta adattativa immune (i.e. 
citochine, chemochine e loro recettori), nell’attivazione delle cellule T, nella motilità e 
nell’adesione cellulare6. Ad esempio è stata dimostrata un’associazione significativa 
con MICA 5.1 (major histocompatibility complex class I chain-related gene A 5.1), 
che codifica per una proteina espressa sulla superficie delle cellule epiteliali che lega 
NKG2D, recettore delle NK, e può funzionare da attivatore stress-inducibile della 
risposta immune innata; infatti, è stato dimostrato che individui omozigoti per MICA 
5.1 hanno un rischio di sviluppare sintomi gastrointestinali associati alla celiachia 
statisticamente superiore (p<0.05) a quello di individui eterozigoti (OR=2.79, 95% 
Intervallo di Confidenza 1.15-6.79)7. In generale, tutti i loci non-HLA concorrono solo 
per il 3% alla genetica della celiachia, mentre il locus HLA ne spiega circa il 40%; è 
possibile ipotizzare quindi che altri meccanismi, ad esempio di tipo epigenetico, 
possano contribuire a spiegare il restante 57% ancora sconosciuto, fornendo così 
nuovi chiarimenti alla patogenesi della malattia.  
 
microRNA 
I microRNAs (miRNAs) sono piccoli RNA non codificanti di circa 21 nucleotidi prodotti 
da trascritti che formano strutture stem-and-loop; sono processati da differenti enzimi 
quali una RNAasi III Drosha e una proteina Pasha in Drosofila o DGC8 nei 
Mammiferi8. E’ noto nell'uomo che, dal 30% al 50% dei geni è regolato da 
meccanismi microRNA-dipendenti; studi iniziali suggeriscono che un dato miRNA 
può regolare tanti mRNA differenti e che, al contrario, uno specifico mRNA può 
essere regolato da più di un miRNA. In generale, dati in letteratura supportano l’idea 
che i miRNA siano repressori della trascrizione, ma recentemente è emerso che 
possano essere anche attivatori della trascrizione in certe condizioni, come ad 
esempio in specifici momenti del ciclo cellulare. Il ruolo dei microRNA è stato 
confermato in molti processi fisiologici, tra i quali la proliferazione, il differenziamento, 
l’apoptosi e la tumorigenesi; ad esempio, è stato dimostrato un coinvolgimento dei 
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miR-155, miR-146, miR-223 e miR181a nella regolazione della risposta immune, 
facendo supporre cosi, che una loro alterata espressione possa compromettere il 
sistema immunitario, determinando lo sviluppo di cancro e patologie autoimmunitarie 
come la CD. Infine recentemente è stato identificato il pattern di espressione dei 
miRNA nell’intestino del topo, suggerendo un ruolo chiave per queste molecole 
anche nell’omeostasi intestinale. 
 
Cenni sulla fisiologia del piccolo intestino e sul pathway di Notch 
L’epitelio intestinale consiste di cellule in rapida proliferazione ed in continuo 
differenziamento, specializzate in specifiche funzioni, che permettono a tale tessuto 
di assorbire nutrienti ed acqua dal cibo ingerito e fornire una barriera tra il lume 
intestinale e la mucosa sottostante. L’unità funzionale del piccolo intestino è 
rappresentata dall’asse cripta-villo; le cellule staminali che risiedono alla base della 
cripta, sono in continua proliferazione e originano progenitori che differenzieranno in 
4 tipi cellulari: gli enterociti con funzione assorbitiva, le cellule di goblet secernenti 
muco, quelle enteroendocrine secernenti ormoni (come la serotonina, la sostanza P 
e la secretina) e quelle di Paneth secernenti peptidi antimicrobici ed enzimi come 
criptidine e lisozimi. Mentre il differenziamento di enterociti, cellule enteroendocrine e 
cellule di goblet avviene durante la migrazione dalla cripta all’apice del villo, le cellule 
di Paneth completano il loro differenziamento alla base della cripta. L’omeostasi 
intestinale è regolata dall’interazione di diversi pathways, tra cui WNT, BMP e 
Notch9. I geni Wnt codificano per glicoproteine secrete ricche in cisteina, che si 
legano a specifici recettori attivando una via di trasduzione del segnale in cui la β-
catenina agisce regolando l’attività del fattore trascrizionale Tcf. Il complesso β 
catenina-Tcf si lega al DNA e attiva la trascrizione dei geni target come il recettore 
per l’efrina B2 che controlla il corretto posizionamento delle cellule lungo l’asse 
cripta-villo, e la Bone Morphogenetic Protein 4 (BMP4), che regola, tramite un 
feedback negativo, il signaling di Wnt. Questo meccanismo risulta dunque essenziale 
per una proliferazione corretta e per il posizionamento delle cellule staminali o 
differenziate nelle cripte intestinali o nel villo. Anche Notch è coinvolto nell’omeostasi 
dell’intestino poiché regola il destino delle cellule staminali nelle cripte promuovendo 
il loro differenziamento in senso assorbitivo. Nei Mammiferi sono state identificate 4 
isoforme del gene Notch (Notch 1-4), che appartiene ad una famiglia di recettori 
transmembrana; dopo interazione con specifici ligandi (DLL1,3,4 e Jagged 1-2), 
Notch subisce tagli proteolitici che permettono la traslocazione nel nucleo del suo 
dominio catalitico dove attiva la trascrizione di specifici geni, interagendo con vari 
regolatori trascrizionali come Hes. La prima evidenza che il pathway di Notch ha un 
ruolo nel differenziamento intestinale, si è avuto in esperimenti con topi knockout per 
Hes1, in cui si ha un differenziamento solo di cellule secretive; inoltre è stato 
dimostrato che Math1, gene represso da Hes1 è necessario per il differenziamento 
verso le linee secretive, poiché topi con Math1 mutato presentano un epitelio 
popolato solo da enterociti. Questi dati nel complesso suggeriscono che il pathway di 
Notch ha un ruolo chiave nel destino delle cellule intestinali, indirizzando il loro 
differenziamento in enterociti, e che Hes1 e Math1 svolgono un’azione opposta nella 
scelta in senso assorbitivo o secretorio.  
 
 Scopo del progetto 
 
I miRNA sono regolatori dell’espressione genica, ed è perciò plausibile pensare che 
alterazioni nella loro regolazione e/o nell’espressione di specifici mRNA da essi 
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regolati, possano compromettere la normale funzione cellulare e contribuire alla 
patogenesi di numerose malattie, tra cui anche la celiachia. In letteratura, non sono 
stati descritti fino ad oggi, studi sui cambiamenti nell’espressione genica correlati a 
miRNA nella malattia celiachia; recentemente, però è stato identificato il pattern di 
espressione dei miRNA nell’intestino del topo. Lo scopo di questo progetto è proprio 
quello di identificare il profilo di espressione dei miRNA nella mucosa intestinale di 
celiaci e di controlli, per individuare quelli differentemente espressi nella CD. Si 
potranno così selezionare i geni target di questi miRNA e le vie metaboliche in cui 
sono implicati, al fine di individuare quelli correlati all'insorgenza della patologia. In 
particolare, i miRNA espressi differentemente solo nei celiaci in fase attiva 
permetteranno di valutare quelli più strettamente correlati con l’infiammazione; quelli 
invece differentemente espressi sia in fase attiva che in remissione, forniranno utili 
indicazioni per comprendere le alterazioni nella regolazione trascrizionale globale dei 
geni associati alla CD.  
 
 Risultati e metodologie impiegate 
 
Pazienti 
Tutti i soggetti inclusi in questo studio (età compresa tra 2 e 10 anni), nell’ambito del 
previsto iter diagnostico, sono stati sottoposti a endoscopia gastrointestinale durante 
la quale è stato prelevato un campione della mucosa della seconda/terza porzione 
del piccolo intestino; il tessuto è stato immediatamente diviso in aliquote: un’aliquota 
è stata utilizzata per l’esame istologico richiesto per la conferma diagnostica di CD, 
un’altra aliquota è stata congelata in azoto liquido per la successiva estrazione 
dell’RNA. Inoltre, ad ogni paziente è stato prelevato un campione di sangue 
periferico in EDTA per valutare i parametri biochimici e la suscettibilità alle molecole 
HLA-DQ2/DQ8. Ad ogni partecipante al progetto è stato richiesto il consenso 
informato e lo studio è stato approvato dal Comitato etico della Facoltà di Medicina e 
Chirurgia della Federico II di Napoli. Sono stati selezionati 3 gruppi di pazienti:  
- 17 pazienti con celiachia in fase attiva 
sintomatologia suggestiva di celiachia, positività per i marcatori genetici (HLA-DQ2 
e/o DQ8) e sierologici tipici della CD (tTG), biopsia intestinale con iperplasia delle 
cripte, atrofia dei villi ed infiltrazione linfocitaria. 
- 9 pazienti in remissione  
a dieta senza glutine da almeno 2 anni, negatività per i marcatori anticorpali, biopsia 
intestinale senza iperplasia delle cripte ed atrofia dei villi. 
- 11 controlli  
negatività ai marcatori sierologici tipici della celiachia, biopsia intestinale senza 
iperplasia delle cripte, atrofia dei villi ed infiltrazione linfocitaria. 
 
Analisi dell’espressione dei miRNA nella mucosa intestinale dei pazienti selezionati 
L'RNA totale comprendente anche i miRNA è stato estratto dalle biopsie di pazienti e 
controlli utilizzando il Kit mirVana (Ambion). La qualità e la concentrazione dell’RNA 
sono state valutate rispettivamente mediante elettroforesi e spettrofotometria. L'RNA 
totale è stato retro trascritto per valutare il profilo di espressione dei miRNA mediante 
tecnologia TaqMan Low Density Array (TLDA). E’ una nuova metodologia costituita 
da micro fluidic cards in cui sono depositati differenti saggi di real time per 365 
miRNA umani; la TLDA utilizza un nuovo step di retrotrascrizione (RT) sfruttando 
hairpin-loop RT primers che sono specifici solamente per le specie mature dei 
miRNA. I dati di fluorescenza così generati, sono stati analizzati dal software SDS 
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2.3 (Applied Biosystems) usando il metodo comparativo ∆CT; tale metodo ha 
permesso di confrontare il profilo di espressione dei miRNA dei celiaci in fase attiva e 
in remissione, rispetto ai controlli, al fine di individuare quelli differentemente regolati 
nella celiachia. I risultati sono stati espressi come RQ (Relative Quantification), che 
indica il grado di espressione del target (miRNA) nel campione da analizzare 
(celiaco) rispetto allo stesso target in un campione calibratore (controllo). Sono stati 
considerati sotto- e sovra- espressi quei miRNA rispettivamente con RQ≤0.5 ed 
RQ≥2.0 in almeno 15/17 pazienti con CD in fase attiva (82%) ed in almeno 7/9 
pazienti in remissione (78%). Il controllo endogeno scelto per normalizzare i dati, 
cioè per rendere minime le differenze di espressione relative alla quantità di RNA, è 
l’RNU48.  
 
Identificazione dei miRNA regolati differentemente nei celiaci rispetto ai controlli 
L’analisi del profilo di espressione dei miRNA rivela che 90 dei 365 miRNA testati 
(25%) non sono espressi nel piccolo intestino; oltre il 50% dei miRNA è espresso in 
modo simile tra celiaci e controlli, mentre circa il 20% (22% nei celiaci attivi e 23% 
nei celiaci in remissione) è differentemente espresso tra celiaci e controlli; in 
particolare, 27 e 55 miRNA sono rispettivamente sovra- e sotto- espressi nei celiaci 
attivi; 22 e 62 miRNA invece sono rispettivamente sovra- e sotto- espressi nei celiaci 
in remissione. Tra questi miRNA differentemente espressi, ne sono stati identificati 
30, di cui 9 sovraespressi e 21 sottoespressi, con simili livelli di espressione sia nei 
celiaci in fase attiva che in quelli in remissione. Tra questi miRNA sovraespressi, è 
stato individuato il miR-449a poiché presenta i livelli di RQ più alti: 55.18±16.45 e 
15.43±7.69 (RQ±SEM) rispettivamente nei celiaci attivi ed in quelli in remissione.  
 
PCR Real Time quantitativa per il miR-449a 
Per confermare la sovra-espressione del miR-449a nei celiaci rispetto ai controlli, è 
stato scelto come metodo di validazione la PCR Real Time quantitativa (qRT-PCR) 
perché è rapido, sensibile, ad alto rendimento e richiede minori quantità di RNA, 
rispetto ad altre tecniche di analisi dell’mRNA (i.e. Northern blot). Il risultato ottenuto 
mediante qRT-PCR nei celiaci attivi (RQ±SEM=2.8±0.9) ha confermato quello 
conseguito con la TLDA. 
 
Identificazione dei geni target del miR-449a e dei pathways ad essi correlati 
Diversi programmi bioinformatici sono stati usati per predire i geni target del miR-
449a; tali algoritmi, valutando diversi parametri (i.e. l’appaiamento e la stabilità 
termica miRNA-mRNA, la conservazione ed il numero di siti di legame), predicono i 
geni target con più alta probabilità di legame del miRNA. Per tale scopo è stato usato 
il programma Mirecords che integra 11 algoritmi di predizione diversi; la correlazione 
tra il miRNA e il gene target è stata considerata significativa sulla base della 
predizione di almeno 2 algoritmi. La lista dei geni selezionati in questo modo è stata 
elaborata con GOTM (Gene Ontology Tree Machine) ed in particolare con KEGG 
database per identificare i pathways in cui tali target sono implicati. I pathways sono 
stati raggruppati nei seguenti gruppi funzionali: 
- Organizzazione e funzione cellulare 
- Ciclo cellulare e cancro 
- Biosintesi di macromolecole 
- Metabolismo 
E’ interessante notare che, tra i target più ridondanti, in tali gruppi funzionali ci sono 
geni appartenenti al pathway di Notch, come NOTCH1 (neurogenic locus notch 
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homolog protein 1), KLF-4 (Krueppel-like factor 4), DLL (delta-like 1), LEF1 (lymphoid 
enhancer-binding factor 1) e NUMBL (numb homolog-like). Poiché Notch ha una 
funzione importante nel differenziamento delle cellule staminali intestinali, abbiamo 
investigato tale pathway al fine di valutarne l’eventuale ruolo nella patogenesi della 
celiachia. 
 
Saggio della luciferasi 
Il saggio della luciferasi ha permesso di confermare che l’interazione del miR-449a 
con la 3’UTR di NOTCH1 è specifica e funzionale, suggerendo così che cambiamenti 
nell’espressione di tale miRNA potrebbero effettivamente modulare l’espressione di 
NOTCH1.  
 
qRT-PCR per NOTCH1 ed HES1 
Per confermare l’espressione del messaggero di NOTCH1 e di HES1 (noto gene 
bersaglio di NOTCH1) nel piccolo intestino, è stata allestita una qRT-PCR; nei celiaci 
attivi i livelli di NOTCH1 ed HES1 sono rispettivamente 3.4±1.3 e 2.2±0.6 (RQ±SEM); 
nei celiaci in remissione sono rispettivamente 6.5±4.7 e 4.2±2.9 (RQ±SEM). Tale 
risultato conferma che NOTCH1 ed HES1 sono espressi nel piccolo intestino ed i 
loro livelli sono sovra-espressi nei celiaci rispetto ai controlli.  
 
Analisi immunoistochimica per NOTCH1 ed HES1 
E’ stata poi effettuata un’analisi immunoistochimica, mediante anticorpi specifici per 
NOTCH1 ed HES1 al fine di valutare la loro espressione proteica nel piccolo 
intestino; in particolare i vetrini colorati sono stati sottoposti a scannerizzazione ed i 
files ottenuti sono stati elaborati con Definiens Analyst LS5.0 system (Definiens AG, 
Germany), che permette di contare il numero di cellule positive e di quantificarne il 
segnale. Tale analisi ha evidenziato che le proteine NOTCH1 ed HES1 sono 
significativamente meno presenti (p=0.02) nelle cripte dei celiaci (sia in fase attiva 
che in remissione) rispetto ai controlli.  
 
Analisi immunoistochimica per la β-catenina e MUC-2 
Dati in letteratura suggeriscono che il destino delle cellule staminali intestinali, sia 
controllato non solo da Notch, ma anche dal signaling di Wnt10; a tal fine, per valutare 
la possibile alterazione del pathway di Wnt, è stata eseguita un’analisi 
immunoistochimica usando anticorpi per la β-catenina (proteina essenziale di questo 
signaling) e per MUC-2 (mucina-2, glicoproteina espressa dalle cellule di goblet e 
associata quindi al loro differenziamento). Non ci sono differenze statisticamente 
significative tra celiaci e controlli per la β-catenina e ciò suggerisce che 
probabilmente tale pathway non è alterato nella celiachia; inoltre, la localizzazione 
nucleare della β-catenina è più evidente nelle cripte dei celiaci rispetto ai controlli, 
indicando che il signaling di Wnt è attivo. Invece, il numero di cellule di goblet nelle 
cripte è statisticamente ridotto (p<0.04) sia nei celiaci attivi, che in quelli in 
remissione (numero medio di cellule ± deviazione standard: 18±1.6 e 15±3, 
rispettivamente) rispetto ai controlli (numero medio di cellule ± deviazione standard: 
35.0±7.7). A conferma di tale dato, il numero di cellule di goblet è statisticamente 
ridotto (p=0.04) anche nei villi dei celiaci in remissione rispetto ai controlli (numero 
medio di cellule ± deviazione standard: 7.0±1.8 e 20.0±4.9).  
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 Discussione 
 
Lo studio del profilo di espressione dei miRNA nella mucosa intestinale del piccolo 
intestino, ha permesso di identificare quelli differentemente espressi nei celiaci 
rispetto ai controlli. In particolare, tra i miRNA upregolati nei celiaci, quello più 
espresso sia nei pazienti in fase attiva che in quelli in remissione, è il miR-449a. 
L’analisi bioinformatica ha permesso di identificare come target del miR-449a, geni 
appartenenti al pathway di Notch, noto signaling coinvolto nel differenziamento delle 
cellule staminali intestinali. Dopo aver confermato in vitro, che il miR-449a 
interagisce a livello della 3’UTR di NOTCH1, abbiamo valutato la sua espressione 
proteica mediante immunoistochimica; nei celiaci, sia in fase attiva che in remissione, 
c’è una diminuzione dell’espressione di NOTCH1 rispetto ai controlli solo a livello 
proteico e non del messaggero, e ciò contribuisce a sostenere l’ipotesi che questo 
recettore possa essere regolato a livello post-trascrizionale. Non ci sono differenze 
statisticamente significative tra celiaci e controlli per la β-catenina e ciò suggerisce 
che probabilmente il pathway di Wnt non è alterato nella celiachia; inoltre, la 
localizzazione nucleare della β-catenina è più evidente nelle cripte dei celiaci rispetto 
ai controlli, indicando che tale signaling è attivo. Tale risultato è in accordo con dati di 
western blot ottenuti da Ciccocioppo11 e Juuti-Uusitalo12 in pazienti celiaci e supporta 
l’ipotesi che il pathway di Notch possa agire in modo separato da quello di Wnt, 
come dimostrato da uno studio sui topi8. Invece, il numero di cellule di goblet nelle 
cripte è statisticamente ridotto sia nei celiaci in fase attiva che in quelli in remissione, 
rispetto ai controlli. In accordo con questi dati, anche Ciacci12 e colleghi riportano una 
riduzione di tali cellule nei celiaci, anche se, nel loro studio, la differenza è 
statisticamente significativa solo tra pazienti in fase attiva e controlli (p<0.02). Nel 
topo invece, è stato dimostrato che la riduzione delle cellule di goblet si osserva 
attivando Notch8; questo apparente risultato discordante si può spiegare 
considerando le differenze tra uomo e topo, ma soprattutto l’effetto più complesso 
esercitato dai miRNA su diversi geni, rispetto all’effetto ottenuto “spegnendo” e/o 
“accendendo” un singolo gene. Il minor numero di cellule di goblet determina quindi 
nei celiaci, una diminuita secrezione di muco e quindi un’alterata funzione protettiva 
della superficie dell’epitelio intestinale a contatto con il lume. Ciò determina un 
aumento della permeabilità intestinale, come già osservato sia nei celiaci in fase 
attiva che in quelli in remissione13,14. Da notare che, tra i target del miR-449a, c’e’ 
anche KLF-4, descritto in letteratura come importante regolatore del differenziamento 
delle cellule di goblet nel colon15. Infatti, in topi KFL-4-/- si osserva una diminuzione 
delle cellule di goblet del 90% ed un’espressione di MUC-2 non omogenea 
nell’epitelio, ad indicare che tale proteina e’ indispensabile per la corretta 
maturazione di queste cellule16. Abbiamo così ipotizzato, che anche nel piccolo 
intestino, l’inibizione di KLF-4, mediata dal miR-449a, potrebbe determinare la 
deplezione di cellule di goblet osservata nei celiaci; tale ipotesi è ovviamente da 
dimostrare sperimentalmente. In conclusione, tali risultati potrebbero indicare un 
nuovo evento patogenetico nella CD, contribuendo a spiegare parte del 60% della 
componente genetica ancora sconosciuta. 
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Analysis of microRNAs expression pattern in small intestine of celiac patients 
Celiac disease (CD) is a chronic inflammatory disease characterized by small 
intestinal mucosal injury and nutrient malabsorption in genetically susceptible 
individuals following the dietary ingestion of gluten1. The disease is characterized by 
villous atrophy, intraepithelial lymphocyte infiltration, chronic inflammation and 
activation of lamina propria T cells. The common genetic background in CD is the 
presence of heterodimeric HLA class II molecules DQ2 or DQ8 that account for 
~40% of the genetic predisposition in CD2; several susceptibility loci not related HLA 
have been identified, but their contribution is only 3-4%3. Further, in addition to DNA 
variations, also gene transcription regulation, such as microRNAs (miRNAs) 
mechanism, could be involved in CD pathogenesis. MiRNAs are small non coding 
RNAs regulating basic cellular functions including proliferation, differentiation and 
death4. Indeed, it is easy to conceive that a defective miRNA-based mRNA regulation 
may compromise normal cell function and cause genetic diseases. The aim of this 
project is to perform an extensive study of the different miRNAs expression pattern in 
intestinal mucosa from CD patients at different stages of the disease [17 with active 
CD and 9 at gluten free diet (GFD)] and from 11 controls, to investigate the role of 
these molecules in transcriptional regulation in CD. We detect and quantify the 
expression profiling of 365 mature miRNAs using TaqMan Low Density Array 
methodology and Comparative CT method. Expression profiling revealed that the 
25% of miRNAs tested are not expressed in jejunal intestine. Among the large set of 
expressed microRNAs over 50% of miRNAs are expressed at similar levels in CD 
and in control patients whereas respectively, the 22% and 23% of miRNAs were 
differently expressed in active CD and in GFD patients vs controls. Among these 
miRNAs upregulated, miR-449a shows very high levels: 55.18±16.45 and 15.43±7.69 
(RQ±SEM) in active CD and in GFD children respectively. The quantitative RT-PCR 
confirmed the high level of miR-449a in active CD patients vs controls (mean 
RQ±SEM: 2.8±0.9). The bioinformatic analysis identified several target genes of miR-
449a, belonging to Notch pathway such as NOTCH1, KLF-4, DLL, LEF1 and 
NUMBL. Notch signaling is a gatekeeper of the progenitor/stem cell compartment of 
the intestine5. The luciferase reporter assay confirmed that the effective, specific and 
functional interaction between miR-449a and NOTCH1. The quantitative RT-PCR 
confirmed the expression of NOTCH1 and HES1 (a target gene of NOTCH1) mRNAs 
in active CD patients (RQ±SEM: 3.4±1.3 and 2.2±0.6, respectively) and in GFD 
patients (RQ±SEM: 6.5±4.7 and 4.2±2.9, respectively). In addition, 
immunohistochemistry showed that NOTCH1- and HES1- positive cells were 
significantly fewer in CD patients vs controls. Because NOTCH1 signals interact with 
the Wnt pathway to influence the intestinal stem cell fate, we investigated both the 
Wnt pathway and secretory goblet cells. We showed a similar β-catenin expression in 
CD and in control children, suggesting that the Wnt pathway is not altered in CD, and 
a reduced number of goblet cells indicating an altered differentiation in celiac small 
intestine. In conclusion, we investigated miRNA expression in celiac small intestine 
and detected very high miR-449a expression levels in both active CD and GFD 
patients. These data demonstrate an altered miRNA gene regulation in CD patients 
than in controls, in association with a reduced NOTCH1 pathway and with a 
decrease differentiation of intestinal cells towards the secretory goblet cell lineage. 
Our findings suggest a novel pathogenic event in CD. 
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INTRODUCTION 
 
CELIAC DISEASE 
 
Epidemiology 
Celiac disease (CD) is a chronic inflammatory disease characterised by small 
intestinal mucosal injury and nutrient malabsorption in genetically susceptible 
individuals following the dietary ingestion of “gluten”. Environmental factors have also 
been reported to exert an important role. This pathology is characterized by the 
presence of anti-tissue transglutaminase antibodies in the serum and by damage at 
the level of the small intestine with villous atrophy, intraepithelial lymphocyte 
infiltration, chronic inflammation and activation of lamina propria T cells. The currently 
estimated prevalence is 1%, with a statistical range of probability of 0.5-1.26% in the 
general population in Europe and USA1-2. The prevalence of biopsy-proven celiac 
disease in Italian school children was reported to be 1:1063. The true prevalence of 
CD is difficult to estimate because of its different presentation, particularly in 
presence of few or no symptoms (underestimated cases); moreover, advances in 
diagnostic methods and improvement in screening have played a part in the increase 
observed. The prevalence of CD is increased in subjects with elevated 
aminotransferase levels, autoimmune diseases and chromosomal aberrations. For 
example, the prevalence of autoimmune thyroiditis (AT) in CD is about 4 times 
greater than that found in the age matched Sardinian schoolchildren background 
population, indicating that CD is a risk factor predisposing to AT4. A large multicenter 
study in the United States showed an increased CD prevalence in high-risk groups, 
including patients with autoimmune insulin-dependent diabetes mellitus (AIDDM), 
Sjogren’s syndrome, osteoporosis, Down syndrome5 and first-degree relatives of CD 
patients. These findings raise interesting questions as to whether abnormal immune 
responses at the level of the gut mucosa, when exposed to environmental antigens, 
have a role in systemic autoimmune disease, or whether these associations reflect 
more an underlying genetic predisposition. Proposed mechanisms of association 
include abnormal regulation of intestinal permeability and increased autoantibody 
production in the setting of chronic gut inflammation6. 
 
Clinical features and Diagnosis 
The first case of CD was described by Aretaeus of Cappadocia, living in the second 
century, which recorded a malabsorptive syndrome with chronic diarrhoea7. 
The typical jejunal damage associated with active celiac disease, showing villous 
atrophy, crypt hypertrophy and increased intraepithelial lymphocyte count, was first 
described in 1957 by John Paulley in the UK. The clinical spectrum of celiac disease 
is wide, including cases with either typical intestinal or “atypical” extraintestinal 
features, or silent forms that are occasionally discovered because of serological 
screening8. The variability in the age of onset of symptoms may be dependent on the 
amount of gluten in the diet and other environmental factors such as for example, 
duration of breast-feeding. The classic form of CD in children consists of 
gastrointestinal symptoms starting between 6 and 24 months of age, after the 
introduction of gluten in the diet. Infants and young children typically present with 
chronic diarrhea, anorexia, abdominal distension, abdominal pain, poor weight gain 
or weight loss and vomiting. Severe malnutrition and even cachexia can occur if the 
diagnosis is delayed9.  
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According to the revised criteria of the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) and European Society for 
Paediatric Gastroenterology and Nutrition (ESPGN), the diagnosis of celiac disease 
is firstly based on the characteristic small intestinal mucosal abnormalityies on 
histological examination of a biopsy specimen10. The lesion in CD is localized in the 
proximal part of the small intestine; the duodenal histology showed intraepithelial 
lymphocytosis, crypt hyperplasia and various degree of villous atrophy. The small 
intestinal mucosal abnormalities are classified according to Marsh criteria in 3 
groups. Marsh I comprises normal mucosal architecture in which the villous 
epithelium is markedly infiltrated by lymphocytes only when the lymphocytosis score 
is >30 (30 lymphocytes per 100 enterocytes); a hyperplastic lesion comprising 
enlarged crypts in which immature epithelial cells are being generated at an 
increased rate, accompanied by an influx of inflammatory cells, characterizes Marsh 
II. Marsh III comprised a large spectrum ranging from minor to severe destructive 
lesion and for this reason is classified into three subgroups as follows: Marsh IIIA, in 
which shortened blunt villi are associated with a mild infiltration of lymphocytes in 
epithelial cells, accompanied by enlarged and hyperplastic crypts; Marsh IIIB, clearly 
atrophic but still recognizable villi, with the addition of enlarged crypts whose 
immature epithelial cells are being generated at an more increased rate, 
accompanied by an influx of inflammatory cells; and Marsh IIIC, nearly total absence 
of villi, with severe atrophic, hyperplastic, and infiltrative lesions11 (Figure 1). 
Secondly a clear cut clinical remission has to be observed on a strict gluten free diet 
(GFD) with relief of all symptoms of the disease. In asymptomatic patients, however, 
a control biopsy is needed to prove mucosal recovery when the patient is taking a 
gluten free diet. Although an intestinal biopsy is still considered necessary to confirm 
the diagnosis of CD, serological tests are frequently used as screening method; they 
include anti-gliadin IgA and IgG (AGA), anti-endomysium IgA (EMA) and anti-tissue 
transglutaminase IgA (tTG or TG2) antibodies. The single most sensitive and specific 
serologic marker of celiac disease is the IgA anti-tTG or anti-EMA11. These 
antibodies are present at diagnosis in a child with typical abnormalities in small 
intestinal mucosa, and they disappear in parallel to a clinical response to a gluten 
free diet12. Measurement of serum concentration of tTG-IgA is often recommended 
for initial testing because of its high sensitivity and specificity for celiac disease. In 
symptomatic individuals, the positive predictive value of EMA and tTG assays for 
finding biopsy evidence of CD approaches 1.00 and the probability of identifying a 
celiac enteropathy at the small intestinal biopsy is almost 100%13. In screening-
identified individuals, AGA+EMA, EMA alone and tTG alone have positive predictive 
values for biopsy evidence of CD ranging from 0.6 to 1.0012. Recently a new test 
detects antibodies binding synthetic deamidated gliadin-related peptides (DGPs)14. 
Although their sensitivity for CD is lower than that of EMA and tTG, DGP-AGA IgG 
has a very high specificity (98.9%) for CD14. In addition, a novel non-invasive method 
[sensitive fluid-phase radioimmunoassay (RIA)] can detect tTG autoantibodies (tTG-
Ab) in saliva; the correlation between saliva and serum tTG-Ab titers was r=0.826, 
p=0.0142. Patients with so called “potential” celiac disease show positivity of serum 
celiac autoantibodies despite a (nearly) normal histological picture at the small 
intestinal biopsy. In many of these cases, the deterioration of jejunal architecture 
takes place over time. Implementation of the gluten-free diet is indicated in potential 
celiac disease, both for treating symptoms and for preventing late-onset 
complications. 
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Marsh I 
A normal mucosal architecture in which 
villous epithelium is infiltrated by 
lymphocytes. (25X; inset, 100X). 
 
Marsh II 
Near-normal villi. A hyperplastic lesion 
comprising enlarged crypts and infiltrated 
by lymphocytes. (50X). 
Marsh IIIA 
Partial villous atrophy with shortened 
blunt villi infiltrated by lymphocytes and 
hyperplastic enlarged crypts. (25X). 
Marsh IIIB 
Subtotal villous atrophy, clearly atrophic 
villi but as such still recognizable, and 
elongated hyperplastic crypts in which 
immature epithelial cells are being 
generated at an more increased rate, 
accompanied by an influx of 
inflammatory cells. (25X). 
Marsh IIIC 
Total villous atrophy, nearly total 
absence of villi, and severe atrophic, 
hyperplastic, and infiltrative lesion. (25X). 
 
Figure 1. Marsh classification used to identify small intestinal mucosal abnormalities in 
celiac patients’ diagnosis. 
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Conversely, so-called “seronegative celiac disease” is characterized by clinical, 
genetic, and histological data indicating celiac disease in a patient lacking serum tTG 
and EMA antibodies. Seronegative celiac disease is likely to be underestimated due 
to the tendency to perform small intestinal biopsy only in patients with positive CD 
serum markers (so called self-fulfilling prophecy). A peculiar type of seronegative 
celiac disease is found in patients that also have IgA deficiency, who usually lack IgA 
but often show IgG class celiac autoantibodies. In these cases, the detection of IgG 
anti-tTG deposits strongly suggests celiac disease. For unknown reasons the 
prevalence of selective IgA deficiency occurs in 1.7% to 2.6% of patients with celiac 
disease, which is a 10- to 16-fold increase over that in the general population15-16.  
Finally, a family history of celiac disease adds evidence to the diagnosis. 
 
Pathogenesis of Celiac Disease 
The pathogenesis of CD is only partly understood but involves a clear interaction 
between environmental (trigger and cofactors) and genetic factors (Figure 2). 
 
Environmental factors 
 
- Environmental trigger 
Among the chronic inflammatory HLA-associated diseases, CD is the unique in that a 
critical environmental factor has been identified. Infact, the major known 
environmental factors required for disease activation are proteins present in the 
dietary cereal grains wheat, rye, and barley. Harmful molecules, collectively called 
“gluten”, are composed of two fractions called prolamines and glutelin. The term 
prolamine and glutelin are generic terms applicable to similarly extracted protein 
fractions from all cereals, whereas the terms gliadin and glutenin describe those two 
groups specifically in wheat. The gliadin fraction is defined on the basis of its 
extractability in aqueous alcohol solution and its very high contents of proline (~15%) 
and glutamine (~30%); glutenin is defined by its insolubility in alcohol solution and by 
its extractability in diluted acid or alkali. The main toxic components of gluten are 
gliadins. More than a hundred components have been identified; they can be 
grouped into four main types (ω5-, ω1.2-, α/β-, γ-gliadins). Glutenins can be divided 
into groups of high molecular weight and low molecular weight, but immunogenicity 
and toxicity have been shown only in the high-weight group. Prolamines with a 
similar aminoacid composition to the gliadin fractions of wheat have been identified in 
barley (hordeins) and rye (secalines), and show a close relation to the taxonomy and 
toxic properties of wheat cereal that affect people with celiac disease. Toxicity of 
related proteins in oats remains debated. Although several gluten epitopes are 
immunostimulatory, some are more active than others. An immuno dominant peptide 
of 33 aminoacids (residues 57-89)17 and a 25-mer (p31-43)18, identified from an α-
gliadin fraction, have functional properties attributable to many proline and glutamine 
residues. Particularly, the 33-mer peptide is of notable interest due to the presence of 
three distinct T-cell epitopes that were identified previously in T-cell proliferation 
assays, namely, PFPQPQLPY, PQPQLPYPQ (three copies), and PYPQPQLPY (two 
copies), all recognized by DQ2 molecules19. Proline gives the peptide increased 
resistance to gastrointestinal proteolysis (in people with and without CD) and causes 
a left-handed helical conformation, which strengthens binding with HLA-DQ2 and 
HLA-DQ8 molecules on antigen-presenting cells (APC); the result is a stable 
complex that can be efficiently recognized by T cells. Additionally, glutamine residues 
are a preferred substrate for tTG-mediated deamidation, which confers an enhanced 
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Figure 2. Causative factors in celiac disease. 
(From The Lancet, 2009). 
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immunogenicity; tTG is constitutively expressed in the intestinal lamina propria and 
transiently activated upon tissue damage. It plays a physiological role in tissue repair 
by promoting protein cross-linking via the formation of isopeptide bonds between 
lysine and glutamine residues. In active celiac disease, the expression of tTG is 
increased and it is considered to be the predominant autoantigen for this pathology. It 
has been suggested that tTG cross-linked to gluten can be recognized as a hapten 
and stimulate the production of specific IgA. This attractive hypothesis to explain the 
appearance of CD specific autoantibodies, however, could not be demonstrated even 
though the disappearance of autoantibodies occurs with a gluten-free diet. So, CD is 
the result of the “civilized” human diet becoming rich in gluten-containing grains and 
the coincidence that protease-resistant peptides derived from partially digested 
gluten contain motifs that favour their deamidation by intestinal tTG and enhance 
their binding to DQ2 and DQ8 molecules20. In addition, gluten can trigger CD8+ T cell 
responses in the lamina propria and may expand the intraepithelial lymphocyte 
population independently of HLA presentation. How the immunogenic gluten peptides 
reach the lamina propria from the intestinal lumen remains controversial. There is 
evidence of a paracellular pathway through defective tight junctions (TJ), but other 
studies showed that much of the transport occurs via epithelial transcytosis, 
especially in the inflammed mucosa of patients with celiac disease. A third but yet 
unproven possibility is the sampling of gluten peptides by lamina propria dendritic 
cells (DCs). This latter was shown in mice but not in humans; DCs can infact project 
protrusions between intestinal epithelial cells reaching the intestinal lumen. For the 
transcellular pathway, macromolecule uptake occurs by endocytosis, followed by 
fusion with lysosomes (phagolysosomes) with possible degradation of the 
macromolecules before being delivered in the submucosa. Conversely, 
macromolecules crossing through the paracellular pathway reach the submucosa 
unmodified21. Particularly, the paracellular passage of gluten is not proven, but under 
physiologic conditions, access of gliadin to gut associated lymphoid tissue is 
prevented by competent intercellular TJ that limit passage of macromolecules 
(including gliadin peptides) across the intestinal epithelial barrier. Instead, in 
susceptible individuals, the interplay between the initiating stimulus (i.e. gliadin) and 
intestinal cells triggers TJ disassembly. It has been demonstrated an amplified 
expression of zonulin (a protein implicated in the opening of tight junctions) and Th1-
induced changes in the expression, localisation, or phosphorylation of epithelial 
junctional proteins in active disease22. Wapenaar and co-workers identified variants 
in genes coding for tight junctional proteins such as PARD3, MAGI2 and MYO9B20, 
suggesting that heritable factors might contribute to intestinal barrier impairment23.  
 
- Environmental cofactors 
Recent observational studies suggest that the introduction of small amounts of gluten 
while the infant is still breast-fed may reduce the risk of CD. A metaanalysis showed 
that the risk of CD was significantly reduced in infants who were breast-feeding at the 
time of gluten introduction (pooled odds ratio 0.48, 95% CI 0.40-0.59) compared with 
infants who were not breastfeeding during this period. Both breast-feeding during the 
introduction of dietary gluten, and increasing duration of breast-feeding, were 
associated with reduced risk for the development of CD24. Infact, breast milk is not 
only a source of nutrition for the infant during this time, but it also provides antigens 
for the developing immune system to learn and develop appropriate immune 
regulatory mechanisms for maintenance of intestinal homeostasis; milk provides 
bioactive factors that directly modulate immune response development as well as 
 19 
factors that promote colonization of the intestine by bacterial flora, which in turn 
influence immune response development. Particularly, the breast milk cytokines 
present in mammalian milks have the potential to regulate the immune response to 
food antigens in infants because they are capable of inhibiting excess inflammation 
and modulating epithelial proliferation25. The timing of gluten introduction in the diet 
seems also important in the pathogenesis of CD: children exposed to gluten 
containing foods in the first 3 months of life had a 5-fold increased risk of CD 
compared with children exposed to gluten containing foods at 4 to 6 months26. So, an 
optimal window (between 4 and 7 months) for dietary gluten introduction, when 
tolerogenic responses may be promoted, has been suggested by ESPGHAN. Other 
factors such as socioeconomic conditions must contribute to the CD incidence in the 
population because inferior prosperity, standard of hygiene, variation in gut flora, 
infections (such as hepatitis A virus, Helicobacter pylori and Toxoplasma gondii) and 
differences in diet, which are factors involved in the maturation of immunoregulatory 
functions, may in turn precipitate CD development27. Infact, among the environmental 
factors investigated in the development of celiac disease are specific infectious 
agents. A prospective study showed that frequent rotavirus infections, the most 
common cause of childhood gastroenteritis, represent an independent risk factor for 
CD in genetically susceptible individuals28. Most children had an infection with 
rotavirus by 3 years of age. Rotavirus infection changes the cytokine balance and the 
permeability in the intestinal mucosa, potentially enhancing penetration of gluten 
peptides and may initiate the immune process leading to celiac disease. If this is the 
case, worldwide implementation of a rotavirus vaccine might diminish the occurrence 
of this pathology. In addition, it is well known that the intestinal microbiota impacts 
the integrity and maturation of the gut immune system and may therefore modulate 
immune host responses to dietary antigens29. Infact, probiotic strains can differently 
modulate both the innate and adaptive immune responses in DQ8 transgenic mice, a 
model of gluten sensitivity; for example, L. Fermentum and L. plantarum were able to 
stimulate the lipopolysaccharide (LPS)-inducible interleukin-12 (IL-12), a critical Th1-
skewing cytokine that elicits interferon-γ (IFN-γ) production by T cells and by natural 
killer (NK) cells; B. lactis, L. plantarum and L. paracasei were able to induce high 
levels of tumor necrosis factor-α8 (TNF-α) in DCs30. 
 
Genetic Factors  
- HLA Class II Genes 
The strong genetic influence in CD is apparent, as the concordance rate in 
monozygotic twins is ~75%, whereas in dizygotic twins is 20% and in first degree 
relatives is 10%31. The common genetic background in CD is the presence of 
heterodimeric HLA class II genes HLA-DQ2 or HLA-DQ8. It is currently estimated 
that HLA genes account for ~40% of the genetic predisposition in CD32 and there is 
an increased frequency in females (94%) compared with males (85%) of celiac 
disease (p=1.6x10−3) in Italy33. The class II molecules, encoded on CELIAC 1 locus 
(Chr. 6p21.31), are expressed on APC, mainly macrophages, DCs and B cells. 
These molecules conferred CD susceptibility by promoting the presentation of gluten 
peptides to the intestinal adaptive immune system; this can lead to activation of 
gluten-specific CD4+ T-helper 1 (Th1) cells in the lamina propria that are central 
effector cells of the intestinal inflammation resulting in crypt hyperplasia and villus 
atrophy. Infact, the derivation of DQ2/8-restricted gluten specific CD4+ T cell clones 
from duodenal lamina propria of CD patients, was the first evidence that these 
molecules conferred susceptibility to CD. Approximately 5-10% CD subjects express 
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the HLA-DQ8 heterodimer and the 90-95% of patients express HLA-DQ2 
heterodimers34. The DQ8 molecule is encoded by an α- and a β-chain encoded by 
HLA DQA1*0301 and HLA-DQB1*0302, respectively; unlike some other HLA-DQ 
alleles, DQ8 does not have an aspartate residue at position 57 of the β-chain 
(Aspβ57). This polymorphism has been shown to be important in determining 
susceptibility to type 1 diabetes and may also be important in CD. The lack of 
Aspβ57 in DQ8 creates a large, positively charged P9 pocket in the peptide binding 
groove and also seems to select T cell populations, responding to non-charged 
native (not deamidated) peptides, that express T cell receptors (TCRs); the TCRs’ 
CDR3β loop (with negatively charged residues) interacts with positively charged 
structures of DQ8, thereby stabilizing the weak interaction between the native gluten 
peptide and DQ8. TCRs were shown to cross-react with the deamidated gluten 
peptide and can therefore also be involved in T cell responses after tTG becomes 
activated. Once tTG is activated, the T cell response becomes directed towards the 
deamidated version of the peptide, which binds with higher affinity to DQ8 and does 
not require TCRs with CDR3β loop. Together, these findings led us to propose a 
model in which DQ8 association with CD can be explained by its ability to select 
distinct but cross reactive TCRs in response to native and deamidated peptides and 
thereby amplify the gluten-specific T cell response. There are two DQ2 isoforms, 
termed DQ2.5, (the α-chain is encoded by HLA-DQA1*0501 and the β-chain is 
encoded by HLA-DQB1*0201) and DQ2.2 (encoded by HLA-DQA1*0201, HLA-
DQB1*0202). Particularly, DQ2.2 molecule, is highly homologous to DQ2.5 but has 
on its own a very low risk for celiac disease35. Yet these molecules DQ2 have very 
similar peptide-binding motifs and both present gluten T cell epitopes. The DQ2.5-
APCs had greater stability of bound peptides and protracted gluten presentation 
relative to that of DQ2.2-cells (Figure 3). The improved ability of DQ2.5 to retain its 
peptide cargo can be ascribed to the presence of phenylalanine (in DQ2.2) instead of 
tyrosine (in DQ2.5) at DQα22, which led to a lower binding stability for most peptide 
ligands. Koning and colleagues proposed a quantitative model for CD development 
involving a threshold effect, in which the number of gluten peptide-HLA (DQ2 or 
DQ8) complexes expressed on the surface of APCs, is a limiting factor that defines 
the magnitude of the gluten-specific CD4+ T cell response and the consequent 
induction of intestinal tissue damage36. This model was based on the finding that 
susceptibility to CD is higher in individuals who are homozygous for DQ2 or DQ8 
than in individuals who are heterozygous for these alleles, suggesting gene-dose 
effects of the HLA-DQ molecules. Newly, it was extimate the risk associated with 
different DQ genotypes, to recognize individuals will develop CD; the study was 
conducted in four European populations and the genetic risk could be stratified into 
five classes (G1 to G5) according to their HLA-DQ genotype. Briefly, in all 
populations, the risk is highest for group G1 (people that have two copies of 
DQB1*02 alleles) and the relative risks for the other genotypes vary between 
European countries37. Another study in Italy, evaluated the CD risk in sibs of celiac 
children; for example, sibs of CD probands have an average recurrence risk of 10%, 
but this average can be broken down according to HLA DQ information from the 
proband (Figure 4). Depending on this information, the risk estimate for the sib 
ranges from 2% to 14%38. Generally, it suggests that the risk estimate ranged from 
0.1% to 29% when HLA-DQ information of the proband, parents and sib was 
considered. Only part of the familial aggregation observed for celiac disease seems 
to be explained by the HLA genes; in addition, not all DQ2/8 individuals develop CD, 
indicating that these HLA genotypes are necessary, but not sufficient for CD 
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Figure 3. The two types of HLA-DQ2 molecule: HLA-DQ2.5 (encoded by HLA-
DQA1*05 and HLA-DQB1*02) and HLA-DQ2.2 (encoded by HLA-DQA1*0201 
and HLA-DQB1*02). Only HLA-DQ2.5 is a strong risk factor for celiac disease 
because binds gluten peptides with higher kinetic stability and allows longer 
gluten presentation than HLA-DQ2.2. 
(Modified from Nature Review Immunology, 2009). 
 
 
 
 
 
 
 
Figure 4. Risk for a sib of a proband according to the DQ genotype of the parents. 
(From Gut, 2007). 
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development. Infact, DQ2 or DQ8 are expressed in 30%-35% of the populations 
where celiac disease is prevalent, with only 2%-5% of gene carriers developing 
celiac disease12. Therefore, additional risk factors probably play a role. 
 
- Non-HLA Genes  
The identification of HLA heterodimers as the major predisposing factor and of its 
role in the development of an intestinal inflammatory CD4+ T cell response to gluten 
established a decisive link between the triggering environmental factor and the major 
predisposing gene; however, the puzzle remains incomplete because it’s still unclear 
why only a subset of individuals with at risk HLA develop CD, and why some so do 
very early in infancy closely after their first exposure to gluten, whereas others 
develop the disease much later in adulthood. So, additional susceptibility loci not 
related to HLA have been identified by genome-wide association studies [large-scale 
case control-based association studies using single nucleotide polymorphisms 
(SNP)], genetic linkage study (identification of chromosomal regions that likely 
contain disease-causing genes in families with a high prevalence of CD) and 
candidate gene association study (candidate genes, selected on the basis of current 
understanding of CD immunopathology, tested for association with CD); each of 
these loci was estimated to be associated with only a small risk of developing celiac 
disease. The susceptibility loci that have been identified are 1239 and are 
summarized in Table 1. Most of these loci contain immune-related genes, in 
particular genes implicated in the control of the adaptive immune response [integrin 
(i.e. ITGA4 at 2q31), chemokines, cytokines and their receptors (IL2 and IL21 at 
4q2740, IL18RAP at 2q11-2q12, IL12A at 3q25–3q26, CCR1 and CCR3 cluster locus 
at 3p2141), in T-cell activation (i.e. TAGAP at 6q23.3)41-42, and in maintaining cell 
adhesion and motility (i.e. LPP at 3q28)43. Furthermore, researchers report that 
additional susceptibility might be conferred by CELIAC344-45 that encodes the 
negative costimulatory molecule CTLA4, and CELIAC446, which contains the myosin 
IXB gene variant encoding an unconventional myosin that alters epithelial actin 
remodelling. A recent study demostred that the major histocompatibility complex 
class I chain-related gene A 5.1 allele (MICA 5.1, ligands for NKG2D) occurred more 
frequently in CD patients than in controls (p<0.05), and that the 5.1/5.1 homozygous 
genotype increased the risk of gastrointestinal symptoms associated with celiac 
disease (OR=2.79, 95% CI 1.15-6.79). The notice that most of these genes encode 
proteins involved in immunity47 supports the notion that CD is an immune-related 
disorder and possibly provides clues on the immunopathogenesis of CD. However, 
the overall genetic contribution of these polymorphisms combined was estimated at 
only 3%-4%12.  
 
The innate and the adaptive immunity 
The immune system, built up progressively during evolution to fight pathogens, 
involves both innate and adaptive mechanisms. The innate system has a dual 
function in mammals: a role of immediate barrier albeit with low specificity and no 
memory, and a second role of antigen-presentation to the adaptive immune system 
via MHC molecules. The adaptive immune system relies on B and T lymphocytes to 
permit a delayed but highly specific response endowed with long-term memory. 
While the immune system has evolved to allow efficacious 
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Table 1. Loci non related to HLA in Celiac Disease Susceptibility.  
 
* GWAS: genome-wide association studies; SNP: single nucleotide polymorphism. 
(Modified from Gastroenterology, 2009). 
 
Loci 
identified 
Type of study used 
for identification 
Origin of the 
cohort(s) 
Candidate genes 
(function) 
CELIAC 2 
5q31-q33 Linkage analysis 
Italy, Finland, 
Scandinavia, Europe 
(metaanalysis) 
Unknown 
CELIAC 3 
2q33 
Candidate gene 
approach 
France, The 
Netherlands, 
Sweden, Norway 
CTLA4 
(T cell response) 
CELIAC 4 
19p13.1 Linkage analysis Netherland 
Myosin IXB 
(Rho family Guanosine 
triphosphatase) 
CELIAC 5 
15q11-q13 
Linkage analysis 
(microsatellite) Finland Unknown 
CELIAC 6 
4q27 GWAS (SNPs)* 
United Kingdom, 
Netherland, Ireland, 
Italy, United States, 
Scandinavia 
KIAA1109, TENR 
(ADAD1) 
IL2, IL21 
CELIAC 7 
1q31 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland, 
Italy, United States 
RGS1 
(B-cell activation) 
CELIAC 8 
2q11-q12 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland 
IL18RAP 
IL18R1 
CELIAC 9 
3p21 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland, 
Spain 
CCR1 (chemokines), 
CCR2, CCRL2,CCR3, 
CCR5, XCR1 
CELIAC 10 
3q25-q26 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland, 
Italy, United States 
IL12A 
CELIAC 11 
3q28 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland, 
Italy, United States 
LPP 
(zinc binding protein) 
CELIAC 12 
6q25.3 GWAS (SNPs) 
United Kingdom, 
Netherland, Ireland, 
Italy 
TAGAP 
(T cell activation) 
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protection against pathogens of increasing sophistication, the counterpart has been 
the appearance of detrimental immune responses against self antigen or harmless 
antigens derived from the environment. CD is a well example in which an 
environmental factor, cereal derived-gluten, can induce an inappropriate immune 
reaction in genetically predisposed individuals and simultaneously promote immune 
reactivity against self antigens (Figure 5). The adaptive immunity plays a central role 
in intestinal inflammation and provides an undisputable link between the two main 
genetic and environmental factors. Infact, in the small intestinal mucosa, pathogenic 
gluten-specific CD4+ T cells are central effectors of the intestinal inflammation3,48. 
Activated CD4+ T-cells produce high levels of pro-inflammatory cytokines (i.e. TNF-α, 
IL-6, IL-18, IL-12 and IL-21) thus inducing a Th1 pattern dominated by IFN-γ. TNF-α 
triggers intestinal fibroblasts to secrete matrix metalloproteinases (MMPs), wich leads 
to mucosal destruction by dissolution of connective tissue. In vivo, expression of 
MMP-1 and MMP-3 mRNA is increased in fibroblasts of celiac small bowel mucosa.  
Additionally, through the production of Th-2 cytokines (i.e. IL-4), activated CD4+ T-
cells drive the activation and clonal expansion of B cells, which differentiate into 
plasma cells and produce antigliadin and anti-tTG antibodies. By interacting with the 
extracellular membrane-bound tTG (mtTG), tTG-autoantibody deposits in the 
basement-membrane region might induce enterocyte cytoskeleton changes with 
actin redistribution and consequent epithelial damage. IFN-γ will in turn lead to higher 
expression of the HLA-DQ molecules and thereby, to increased gluten peptide 
presentation. Key factors that influence the efficiency of gluten presentation include: 
- the level of gluten intake 
- the enzyme tTG which modifies gluten into high affinity binding peptides for 
DQ2 and DQ8 
- the HLA-DQ type, as DQ2 binds a wider range of gluten peptides than DQ8  
- the gene dose of DQ2 and DQ8  
- additional genetic polymorphisms that may influence T cell reactivity49.  
The current idea is that gluten could become a self-amplifying loop that could cause 
limited tissue damage locally. This tissue damage would lead to the release of tTG 
that will modify native gluten peptides into high affinity ligands for DQ2 and/or DQ8, 
thereby expanding the gluten-specific CD4+ T cell responses enhancing the role of 
adaptive immunity; the consequence is an additional tissue damage: the initiation of 
a second self-amplifying loop. Alternatively, it’s possible that infections occurring in 
the gastrointestinal tract would generate a pro-inflammatory milieu that might lead to 
loss of tolerance to native gluten peptides and generate tissue damage 
simultaneously and thus, initiate deamidation by tTG. Once activated, the CD4+ T 
cells drive a Th1 response that leads to the development of typical mucosal celiac 
lesions. Yet, it has become increasingly clear that a highly specific adaptive response 
against gluten is not sufficient to trigger intestinal inflammation; thus, only a subset of 
individuals bearing DQ2/8 develops CD. A complementary mechanism is innate 
immunity, with both a massive increase of intraepithelial lymphocytes (IELs) and 
gluten peptides toxic for patients despite the fact that they are not recognized by 
lamina propria CD4+ T cells. Proteins from wheat, rye, or barley (particularly, α2-
gliadin peptide p31-43/49) which are distinct from peptides that elicit adaptive 
immunity, were shown to trigger innate immunity in intestinal epithelia and intestinal 
organ cultures12. IELs are localized between intestinal epithelial cells at the 
basolateral side of the epithelium and are thought to play an important role in 
immunosurveillance of the epithelium. Innate immune activation of IELs by gluten, 
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Figure 5. Mechanisms of mucosal damage in celiac disease. 
(From The Lancet, 2009). 
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induces up-regulation on the intestinal epithelium, of MICA and HLA-E the ligands for 
NKG2D and CD94/NKG2C, respectively. Interaction of NKG2D and CD94/NKG2C 
with their ligands will enhance IFN-γ production and cytolysis, leading to tissue 
damage; IFN-γ and secreted mediators may cause activation of macrophages which, 
in turn, produce pro-inflammatory cytokines contributing to the damage of the 
mucosal matrix50-51. Particularly, NKG2D also links innate and adaptive immunity, 
because it both triggers antigen-specific lymphocyte-mediated cytotoxicity and 
induces a direct cytolytic function independent of TCR specificity in effector CD8+ T 
cells. Similarly, the NKG2C receptor stimulated IEL proliferation and cytokine 
secretion in patients with CD. IELs can also have an immunoregulatory capacity 
through the secretion of transforming growth factor TGF-β, a negative regulator of the 
immune response. Interleukin-15 (IL-15) has a central role at the interface between 
innate and adaptive immunity in CD in synergy with interleukin-21 (IL-21), a cytokine 
expressed on CD4+ T cells; IL-15 is synthesized both by epithelial and lamina propria 
mononuclear cells and can acts on multiple targets: in the epithelium, IL-15 has a 
direct action on IEL that promotes their survival and accumulation, stimulates their 
production of INF-γ and their cytotoxicity via innate immune NK receptor; IL-15 may 
also directly or indirectly promote the expression of epithelial ligands for these NK 
receptors. These combined effects of IL-15 result in an autoimmune attack of the 
epithelium and promote the emergence of lymphomas. Lymphomas infact, develop 
as a consequence of uncontrolled activation of IELs and provoke a severe 
enteropathy refractory to the GFD. Moreover, IL-15 can acts directly on DCs and 
stimulate their maturation and antigen presentation. This effect of IL-15 is thought to 
bolster the activation of gluten-specific CD4+ LPL. Finally, IL-15 can hamper local 
immunoregulation by blocking the Smad-3 pathway of TGF-β in both IEL and LPL. IL-
15 can thus indirectly promote the release of Th1 cytokines and the cytotoxicity of 
intestinal lymphocytes52. In conclusion, while gluten-specific CD4+ T cells elicit an 
inflammatory response in the lamina propria, IELs in the epithelium acquire activating 
NK receptors and the ability to lyse stressed epithelial cells independent of T cell 
receptor signaling, which likely contributes to the typical tissue damage in CD49. As a 
result, the gluten-specific CD4+ T cell repertoire is substantially expanded, which 
enhances the inflammation and disease development12,49. 
 
Therapy in celiac disease 
The cornerstone treatment of CD remains a lifelong GFD and supportive nutritional 
care in case of iron, calcium and vitamin deficiencies53. A life-long GFD is a well 
tolerated therapy that improves health and quality life in the vast majority of patients 
with celiac disease, even in those with minimal symptoms. This treatment is, 
however, difficult to sustain, owing to small levels of gluten contamination in food 
products, high costs and restricted availability of gluten-free food alternatives, and 
cultural practices leading to a substantial social burden. Restriction of the GFD may 
cause anger, sadness and despair. In a general population-based cohort study, it 
was found that CD was associated with an increased risk of subsequent depression 
(hazard ratio=1.8)54. Allowing patients to occasionally consume small amounts of 
gluten would greatly improve their quality of life. Owing to recent advances in the 
understanding of the pathogenesis of CD, different targets have been identified and 
have motivated the development of several experimental therapeutic strategies. 
These therapies focus on alteration of dietary food products, decrease of gluten 
exposure by rapid enzymatic degradation, inhibition of small intestinal permeability or 
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modulation of the immune response55. Attractive therapeutical targets, but in 
progress, were: 
- The selection of grains with low or absent immunogenic sequences, but with 
reasonable baking properties (detoxification of wheat via genetic alteration to remove 
or scramble the toxic peptides of gluten). 
- The enzymatic degradation of gluten as an attractive alternative strategy for oral 
therapy in CD to abolish its immunogenic and toxigenic activities; for this scope, 
several enzymes, such as prolyl endopeptidase (a gliadin detoxifier), were studied 
following different approaches. 
- The gluten hydrolysis using probiotic bacteria to decrease gluten toxicity ex vivo56-58 
and gluten intolerance in humans59; in the same way as probiotic preparation was 
capable to hydrolyze gliadin peptides responsible for CD60. 
- The inhibition of the permeability using molecules such as AT-1001 that is an 
inhibitor of paracellular permeability; its structure derived from a protein secreted by 
Vibrio cholerae; it was well tolerated and reduced intestinal permeability, 
proinflammatory cytokines production and gastrointestinal symptoms in celiacs 
following gluten exposure61. 
- Inhibition of tTG with molecules such as KCC009 that inhibits intestinal tTG when 
given orally; it’s well tolerated by rodents and it has short serum half-life. 
- The use of anti-inflammatory cytokines to suppress gluten-dependent T-cell 
activation, antibodies neutralizing INF-γ and humanized anti-IL-1556. 
- The improvement of peptide vaccines using α- and ω-gliadin 17-mer peptides62. 
- The improvement of integrin-α4 antagonist and humanized anti integrin-α4β7 as 
potential candidates for CD inflammatory modulation56.  
Therefore, early prevention of CD may represent a cost-effective strategy, as the 
disease is highly prevalent. As pharmacological treatments of CD are not yet 
available, preventive measures (i.e. breast-feeding at the time of gluten introduction 
and dietary gluten introduction at 4-7 months) are regarded as potential options to 
reduce the incidence of the disease. 
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MICRORNAs 
 
MicroRNAs (miRNAs) belong to RNA-mediated silencing pathways that, with DNA 
methylation and modification of core histones, constitute epigenetic machinery. 
Epigenetic mechanisms regulate gene expression and operate at the transcriptional 
and post-transcriptional level of gene activity as well as at the level of protein 
translation and post-translational modifications, in order to determine the phenotype 
without changes in genotype. MicroRNAs are endogenous, non-transcribed but 
functional RNAs of approximately 22 nucleotides, occurring in both plants and 
animals; the first small RNA, lin-4, was discovered in 1993 by genetic screens in 
nematode worms63. MiRNAs are expressed in a tissue-specific manner and function 
as endogenous silencers of numerous target genes; infact, a rapidly growing number 
of publications demonstrate the great importance of these molecules by repressing 
translation or inducing cleavage of mRNA, with implications in cell differentiation, 
metabolism and diseases such as cancer. In mammals, miRNAs comprise 2-3% of 
genes, with ~700 different sequences so far identified in humans (miRBase 14.0 at 
www.mirbase.org/); they are predicted to control the activity of more than 60% of all 
protein-coding genes and participate in the regulation of almost every cellular 
process investigated to date64. MiRNAs are processed from precursor molecules (pri-
miRNAs), which are either transcribed by RNA polymerase II from independent 
genes or represent introns of protein-coding genes. The pri-miRNAs fold into 
hairpins, which act as substrates for two members of the RNase III family of 
enzymes, Drosha and Dicer. The product of Drosha cleavage, an ~70-nucleotide pre-
miRNA, is exported to the cytoplasm where Dicer processes it to an ~20-bp 
miRNA/miRNA duplex. One strand of this duplex, representing a mature miRNA, is 
then incorporated into the miRNA-induced silencing complex (miRISC or microRNP) 
(Figure 6). In this complex, the mature miRNA is able to regulate gene expression, 
binding through partial complementary generally, for the most part to the 3’-
untranslated region (3’-UTR) of target mRNAs, and leading at the same time to some 
degree of mRNA degradation and translation inhibition65. The most stringent 
requirement for this interaction is a contiguous and perfect Watson-Crick base-
pairing of the miRNA 5’nucleotides 2-8, representing the “seed region” nucleating the 
interaction. In addition an A residue across position 1 of the miRNA and A or U 
across position 9 improve miRNA activity, although they do not need to base-pair 
with mRNA nucleotides. Usually, miRNA-mRNA duplexes contain mismatches and 
bulges in the central region (miRNA positions 10-12) that prevent endonucleolytic 
cleavage of mRNA by an RNAi mechanism. AU-rich sequence context and structural 
accessibility of the sites may improve their efficacy66. MiRISC functions as a highly 
modifiable scaffold that associates with specific mRNAs via the bound miRNA and 
facilitates the localized activity of a variety of accessory proteins67. MiRISC contains 
several proteins such as Dicer, TRBP, PACT, GW182 and Gemin3, but the 
components directly associated with miRNAs are Argonaute proteins68. Argonaute 
proteins (AGO) contain four domains: the N-terminal, PAZ, middle, and Piwi 
domains69; the PAZ domain is implicated in the binding of single-stranded RNA while 
the PIWI domain confers the endonucleolytic activity of Argonaute proteins and 
requires coordination of divalent cations by Aspartate-Aspartate-Histidine (DDH) 
motif for catalysis. In animals, some Argonaute proteins can cleave RNA molecules 
while others have lost their catalytic activity and participate in a gene regulatory 
mechanism that does not require RNA cleavage. 
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Figure 6. Biogenesis of microRNAs.  
(From FEBS Journal, 2009). 
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In mammalian cells, four AGO proteins have been identified, all of which can form a 
functional RISC but only Ago2 diplays an endonuclease activity to slice 
complementary RNA sequences between positions 10 and 11 from the 50 end of 
guide strand RNA70. Therefore, human Ago2 is a component not only of miRISC but 
also of RISC assembled with exogenously introduced siRNA (siRNA-induced 
silencing complex, siRISC). GW182 proteins [glycine-tryptophan (GW) repeat-
containing protein of 182 kDa] represent another group of proteins crucial for miRNA-
induced repression71. They interact directly with and act downstream of AGOs and, 
with other components of miRNPs, repressed mRNAs; they are found enriched in 
processing bodies (P-bodies, also known as GW-bodies), which are cytoplasmic 
structures involved in the degradation and storage of translationally repressed 
mRNAs72. MiRNA triggers gene silencing by at least three possible mechanisms73: 
(1) Post-initiation repression 
MiRNA blocks translation after it is initiated and inhibits completion of protein 
synthesis; after translating ribosomes are removed or lost, miRISC-containing 
transcripts are locate to processing P-bodies for storage or RNA destruction.  
(2) Inhibition of translation at the initiation step 
In this model, 5’ cap structures of target mRNA are required for miRISC function; 
binding of Ago2 to m7G-cap prevents the recruitment of eIF4E, an essential 
translation initiation factor in eukaryotic cells. MiRISC could also block the assembly 
of 80S ribosomes by recruiting elF6, which binds to 60S ribosomal subunits and 
prevents their association with 40S subunits, thus preventing translation initiation74-75. 
(3) Direct target mRNA destabilization by inducing its deadenylation and decay76. 
Increased turnover of mRNA results in reduced protein synthesis; target mRNA 
whose deadenylation and degradation have been started by miRNA may relocate to 
P-bodies for accelerated mRNA decay. 
In all three possible pathways, miRISC-targeted mRNAs are sequestered in P-bodies 
for storage or decay. Although the mRNA degradation machinery is predominantly 
concentrated in P-bodies, it is not clear if this process is restricted to P bodies. 
Recently, multivesicular bodies (MVBs) and endosomes were also identified as 
cellular organelles contributing to miRNA function or miRISC turnover77,63. The 
mechanistic details of miRNA’s function in repressing protein synthesis are not well 
understood. Mature miRNAs generated from different miRNA genes may differ in 
length (miRNA length diversity)78-79, and individual miRNA genes may give rise to 
several miRNA species that differ in length (miRNA length heterogeneity)79. Thus, the 
accumulation of structural imperfections in pre-miRNA hairpins may result in the 
higher plasticity of the precursor structures and this may be considered another 
successful strategy for the enrichment of miRNA diversity and increased complexity 
of miRNA regulatory networks. Usually, multiple sites, either for the same or different 
miRNAs, are required for effective repression, and when the sites are close to each 
other, they tend to act cooperatively80. The level of repression achieved is dependent 
on both the amount of mRNA and the amount of available miRNA complexes81. 
Generally, the data in literature supports the idea that miRNAs repress translational 
initiation, but recently advances do not exclude the possibility that the mechanisms of 
miRNA-directed mRNA regulation differ among organisms, among miRNAs, or even 
at different developmental stages. Alternatively, the location of miRNA-binding sites 
within an mRNA or the position of mismatches and bulges within the miRNA-binding 
sites may influence the mechanism by which productive translation is repressed. 
Clearly, much remains to be explained before the molecular basis of miRNA-directed 
translational repression is clear82. 
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During the last years, several groups have reported that miRNAs can activate rather 
than repress their targets under certain conditions71,83-84. Infact, for example, 
Vasudevan and collegues propose that miRNAs oscillate between repression and 
activation in coordination with the cell cycle: in proliferating cells they repress 
translation, whereas in G1/G0 arrest (which often precedes differentiation), they 
mediate activation. This regulation occurs on at least two levels: first, recruitment of 
the microRNP reflects both its expression level and its ability to productively interact 
with mRNA target sites; second, the AGO2 complex must be subject to modification 
because tethered AGO2 differentially regulates translation according to cell growth 
conditions83. MiRNAs expression can be regulated by several mechanisms such as 
inherited mutations and polymorphisms in the primary trascripts of miRNAs and/or 
defects in their biogenesis machinery; also epigenetic mechanisms, such as 
promoter methylation or histone acetylation, can modulate their expression. 
 
Role of miRNAs in the intestine 
As a consequence of their ability to regulate gene expression, miRNAs are involved 
in the most crucial cellular processes, spanning from development, differentiation, 
cell cycle regulation to senescence and metabolism. As with other complex gene 
regulatory networks, aberrant expression or processing of miRNAs could have 
profound effects on cellular function and contribute to diseases. Whereas the 
importance of miRNAs for the development of several tissues is well established, 
their role in the intestine and particularly both in human and in celiac gut, is unknown.  
Recently, McKenna has quantified the complete miRNAs expression profile of the 
mouse intestinal mucosa to determine the contribution of these molecules to gut 
homeostasis85. Particularly, in Dicer1-deficient mice (mice lacking of functional 
miRNAs), intestinal barrier function is impaired, resulting both in intestinal 
inflammation with lymphocyte and neutrophil infiltration, and in disorganization of 
epithelium with a decrease of goblet cell. Another miRNAs expression profile was 
performed in the active ulcerative colitis in mice; particularly, among 11 miRNAs 
differently expressed, miR-192 was downregulated and regulated colonic epithelial 
cell-derived chemokine expression86. Chassin and collegues demonstrate that miR-
146a regulates the responsiveness of intestinal epithelial cells during microbial 
colonization of the neonatal intestine of mice: the upregulation of miR-146a in the 
developing gut is essential to protect the neonatal intestine from mucosal damage 
after introduction of bacteria87. Patients with irritable bowel syndrome (IBS) have 
increased intestinal permeability (such as in celiac disease) that is associated with 
upregulation of miR-29a in blood microvesicles, small bowel and colon tissue88. 
The most studies about miRNAs dysregulation in human, were performed in 
intestinal cancer tissues, such as colorectal tumor samples (in which it was observed 
the down-regulation of miR-143 and miR-145) and gastrointestinal cancers samples 
(in which it was observed the up-regulation of miR-21)89. 
 
MicroRNA-449a 
Human miRNA 449 family (a, b and c) is encoded on chromosome 5q11.2. The 
mature miR-449a (accession number miRBase: MIMAT0001648) sequence is 
evolutionarily conserved across a variety of species (monkey, horse, rodents and 
dogs) and therefore it probably exerts an important function90. It structurally 
resembles the p53-inducible miRNA 34 family mediating cell cycle arrest and tumor 
suppression. Infact, the majority of studies about miR-449 was performed in cancer 
tissue and revealed a proapoptotic role for it; for example it has demonstrate that 
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miR-449 is upregulated in multiple myeloma with t(14;16)91 and it’s one of the highest 
downregulated microRNAs in primary pigmented nodular adrenocortical disease 
(PPNAD)92. In agreement with a putative tumor-suppressive role, miR-449a as well 
as miR-34a reduced proliferation and strongly promoted apoptosis by at least 
partially p53-independent mechanisms93. Infact, miR-449 (both a and b) is a E2F1-
inducible target and negatively regulates E2F activity through a feedback loop 
mechanism. E2F1 is a potent inducer of apoptosis essential for cell proliferation and 
its uncontrolled activity is one of the most widely acknowledged reasons for 
malignant growth. MiR-449 contributes to the due control in two ways, by 
antagonizing E2F1 and also by eliminating the cell when necessary. As both 
mechanisms can occur independently of p53, miR-449 may represent an essential 
barrier to cancer progression in cells that have already lost p53 function through 
mutations. Infact, functional analysis indicates that this inhibitory effect was found to 
be conveyed by directly targeting CDK6 and CDC25A, two oncoproteins that 
positively regulate retinoblastoma protein (pRb) phosphorylation; reduced level of 
CDK6 and CDC25A leads to dephosphorylation and consequently inhibition of E2F1 
activity and cell cycle progression. This negative feedback effect of miR-449 on E2F1 
is distinguishable from other miRNA targets of E2F1 that feedback E2F1 by directly 
decreasing E2F1 expression. Interestingly, the genomic region encoding both miR-
449a and miR-449b is embedded into an intronic sequence of the mRNA-encoding 
gene CDC20B, a paralog of CDC20. Mir-449 thus seems to be regulated through the 
activation of its host gene. Infact, although little is known about the function of this 
gene, its paralog CDC20 is an essential component of the cellular machinery that 
enables the anaphase-promoting complex to destruct its targets in a timely manner, 
allowing progression through mitosis. It is to be noted that several mitosis-promoting 
genes, for example, Polo-like kinase and others, have previously been identified as 
E2F1 targets, implying E2F1 in mitotic progression. It is tempting to speculate that 
E2F1 may further promote mitosis through CDC20B, whereas uncontrolled E2F1 
activity is avoided by building a negative feedback into the same gene. In addition, 
miR-449 gene locus was characterized with bivalent histone methylations, H3K4me3 
and H3K27me3, a chromatin marker associated with gene repression. So, epigenetic 
control of this miRNA in cancer cells could make it more applicable as therapeutic 
targets, because miRNA can be delivered to tumor tissue on site to suppress cancer 
cell growth due to its pleiotropic nature. Thus, restoration of miR-449 expression 
through epigenetic drug treatment may result in inhibition of multiple oncogenic 
signaling in cancer cells94-95. Recently, for its proapoptotic function as well as its 
ability to block cell cycle progression, Lizè and collegues propose miR-449a as a 
sensitive and specific biomarker for the differentiation of bronchial epithelia; infact, 
miR-449a may actively promote also mucociliary differentiation and it may contribute 
to a first line of defence against genotoxic stress96. 
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PHYSIOLOGY OF THE SMALL INTESTINE 
 
The small intestine can be subdivided anatomically from anterior to posterior into 
duodenum, jejunum and ileum, whereas the large intestine is subdivided into colon 
and rectum. The predominant function of the small intestine is absorption of nutrients 
whereas the large intestine compacts the stools. The small intestine is much longer 
in length than the large intestine, and contains villi that dramatically increase the cell 
surface area to more efficiently absorb nutrients97. The epithelium of the small 
intestine is composed of four different cell types: enterocytes, enteroendocrine, 
Paneth cells and Goblet cells (Figure 7). The most abundant cells are enterocytes 
(absorptive cells), which absorb nutrients from the food and secrete hydrolases into 
the lumen. Enteroendocrine cells represent less than 1% of all cell types and secrete 
hormones such as serotonin, substance P and secretin. Paneth cells, which reside at 
the bottom of the crypts of the small intestine, can be seen as the “innate immune 
system” of the intestine as they secrete antimicrobial peptides and enzymes such as 
cryptidins and lysozyme in order to control the microbial flora of the intestine98. 
Finally, goblet cells are mucus-producing cells and are most abundant particularly in 
the large intestine in order to protect the intestinal epithelium as compaction of stools 
increases. Infact, intestinal epithelial cell surface is covered by two mucus layers 
(inner, firmly adherent layer and outer, loosely adherent layer) consisting largely of 
MUC2 mucin network produced by the goblet cells, and other host defense 
molecules produced by goblet cells, Paneth cells and absorptive enterocytes. 
Microbes are associated with the outer, loosely adherent mucus layer, but are absent 
in the inner, firmly adherent mucus layer. Epithelial cell surface is covered by 
glycocalyx, which consists of membrane-bound mucins (MUC3 and MUC17 in the 
small intestine) and other membrane glycoproteins. All cell types are formed in 
crypts, which are bottle-shaped invaginations of the small intestine interspersed 
between finger-like villi; the stem cells reside near the base of the crypt. As the gut 
epithelium is replenished every few days, the cycle of production of new cells 
continues throughout life. For this reason, the average life span of an epithelial cell is 
less then a week, with the exception of Paneth cells, which survive approximately 20 
days. Pluripotent stem cells, localized near the base of the crypt, are characterized 
by rapid proliferation and ascension along the crypt-villus axis, with cessation of 
proliferation and subsequent differentiation into a specific primary cell types. Lifelong 
maintenance of self-renewal requires the presence of long-term stem cells within the 
gut. In the small intestine, at the bottom of the crypts, stem cells give rise to a 
transient population of undifferentiated cells that vigorously proliferate as they 
migrate toward the lumen of the intestine. Substantial evidence suggests two 
populations of stem cells: long-term quiescent (reserved) and actively cycling 
(primed) stem cells. The idea is that baseline regeneration is accomplished by a 
“primed subpopulation” of active stem cells, whereas quiescent stem cells function as 
a reserve subpopulation that responds to injury. These cells are in adjoining locations 
and are presumably maintained by the secretion of specific proteins generated in a 
unique microenvironment or stem cell niche surrounding each population99. The 
relationship between these two populations, as well as the cellular sources and 
composition of the surrounding environment/niche, remains to be defined100. The 
progeny of stem cells migrate in precise patterns; infact, absorptive, enteroendocrine, 
goblet cells migrate toward the villus, while Paneth cells occupy the bottom of the 
crypts; the process in which these cells migrate up towards the tip of the villi, the 
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Figure 7. Distribution of epithelial cell types in the mammalian small 
intestine. a) A villus with one of the crypts that contribute to renewal of its 
epithelium. b) The four classes of terminally differentiated cells. 
(From Nature Review Genetics, 2006). 
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consequent apoptosis and the leakege into the lumen of the intestine is called 
“exfoliation”. In the adult small intestine, it is generally known that the 
microenvironment around the stem cells, called the “niche”, plays important roles in 
the epithelial cell renewal101. Structurally, the stem cell niche mainly consists of 
subepithelial myofibroblasts, which secrete various factors including extracellular 
matrix components, growth factors, cytokines, Wnt and epimorphin. Recent studies 
identified a number of signaling molecules whose localization is associated with the 
crypt-villus axis; although their functions have not yet been clarified enough, a 
growing body of evidence has shown that the Wnt and Notch signaling pathways play 
important roles in the epithelial cell renewal. In addition, it has long been known that 
the modelling of the intestinal epithelium depends on epithelial-mesenchymal 
interactions, and recent data have identified the hedgehog, platelet-derived growth 
factor (PDGF) and BMP signalling pathways as key mediators of these two-way 
communications; infact, mutations in these pathways derange the construction of 
crypts and villi. Moreover, within the epithelium, cells signal to one another through 
the Wnt, Notch and Eph/ephrin pathways: mutations that affect these pathways 
cause marked changes in the distribution of cell types along the crypt-villus axis. The 
challenge is to understand not just the action of each type of signal individually, but 
how the whole set of signals operates as a system to organize the crypt-villus 
architecture and to control the patterning and renewal of the gut epithelium102. 
 
Signaling pathways regulating intestinal homeostasis 
 
- Wnt pathway 
The Wnt pathway is certainly one of the best studied signallings in the intestine due 
to its relevance to gut biology and cancer. Infact, in the intestine, the canonical Wnt 
signaling cascade plays a crucial role in driving the proliferation of epithelial cells.  
Wnts are secreted glycoproteins that mediate cell-to-cell communication during 
development. They bind to the family of Frizzled receptors that are 7 transmembrane 
molecules in a complex with the Low-density lipoprotein receptor related proteins 
(LRP-5 and -6)103-104. Activation of these receptor complexes results in stabilization 
and accumulation of a protein called β-catenin. In the absence of Wnt signaling, β-
catenin is retained in the cytoplasm in a multi-protein complex comprising the tumor 
suppressor APC (Adenomatous Polyposis Coli), the scaffold protein Axin, CK-1 
(Caseine Kinase-1) and GSK-3b (Glycogen Synthase Kinase-3b). In this complex β-
catenin is sequentially phosphorylated by CK-1 and GSK3-b and thereby tagged for 
ubiquitination and proteosomal degradation. Upon activation of the Wnt pathway, 
GSK3-b is inhibited by Dishevelled (Dsh) and β-catenin can no longer be 
phosphorylated at its N-terminus. Unphosphorylated β-catenin is more stable so it 
accumulates in the cytoplasm and translocates to the nucleus where it binds 
transcription factors of the TCF/LEF family thereby activating transcription of 
downstream target genes. 
A large body of evidence shows that activation of the canonical Wnt pathway is 
essential to maintain the crypt cell population in a proliferative state in the 
intestine105; infact, the nuclear accumulation of β-catenin is preferentially observed in 
cells located at the base of crypts and decreases as cells move toward the top of the 
crypts106. This clearly indicates that the transit-amplifying progenitors are under the 
influence of the Wnt signal, whereas terminally differentiated cells, other than Paneth 
cells, are in areas where the canonical Wnt signal is inactive. 
 36 
Consistently, it has been shown that aberrant activation of Wnt signaling, by 
mutations in APC or β-catenin, is strongly associated with the development of 
colorectal cancer because many of the epithelial cells enter into the proliferative state 
and display a failure of the differentiation programs107. Conversely, blockage of 
canonical Wnt signals in the intestine, either through deletion of Transcription Factor 
4 (TCF4) or overexpression of the Wnt antagonist Dickkopf (Dkk)-1, results in 
arrested epithelial cell proliferation107-110; infact, TCF4 knockout mice die soon after 
birth; at the time when the gut epithelium is normally in a highly proliferative phase, 
these mice lacked any proliferative epithelial compartments, and the neonatal 
epithelium was composed exclusively of differentiated, nondividing villous-type cells. 
TCF4 thus appears to have a critical role in maintining intestinal crypt stem cells and 
its mutation has dramatic consequences for intestinal morphogenesis. All these data 
suggest that the Wnt signalling pathway is required for the maintenance of the crypt 
progenitor phenotype111; briefly, when the pathway is overactivated, crypts enlarge 
and when the pathway is blocked, they disappear. In addition, Wnt signaling is 
necessary for positioning Paneth cells near the base of the crypts, and for separating 
proliferating and differentiated cells; infact, the Wnt controls expression of the Ephrin 
sorting receptors and ligands (EphB/ephrinB) that are TCF4 target genes. These 
receptors allow the correct positioning of epithelial cells in a Wnt gradient along the 
crypt-villus axis as well as the positioning of postmitotic Paneth cells at the bottom of 
the crypt112-113. More recent evidence has shown that Wnt may also stimulate cellular 
responses independently of β-catenin and TCF. Examples of these so-called “non 
canonical pathways” involve either the intracellular release of calcium ions and 
activation of Ca2+-dependent kinases or morphogenic changes dependent on RhoA 
and Jun kinase stimulation, also termed the “planar cell polarity pathway”114. Finally, 
β-catenin has an additional role as a component of adherens junctions as it binds to 
the cytoplasmic tail of cadherin proteins thereby linking them to the cytoskeleton of 
epithelial cells. The mechanisms controlling whether β-catenin joins the signaling 
pool or is part of adherens junctions is currently unknown. 
 
- Notch pathway 
The Notch pathway plays a central role in intestinal homeostasis because it is 
involved in the specification of cell fate in a wide variety of cell types and is perhaps 
instructive for the generation of all cells in invertebrates and vertebrates; infact, it is 
highly conserved in evolution and is found in organisms as diverse as worms and 
humans97. Depending on the context, Notch signaling may result in diametrically 
different outcomes, from inhibition or promotion of differentiation to proliferation or 
apoptosis. For this reason, it can interact with a variety of the important signaling 
networks. Key pathways where interactions with Notch have emerged are the 
fibroblast growth factor (FGF) pathway, the transforming growth factor-β (TGFβ) and 
bone morphogenetic protein (BMP) pathway, the nuclear factor kB (NF-κB), Wnt, 
Ras, and signal transducer and activation of transcription (STAT) signaling pathway. 
All these pathways are involved at some stage in gut function and, with the 
widespread expression of Notch in the gut, potentially herald its extensive 
involvement in diverse cellular processes. The Notch genes encode single pass 
transmembrane receptors that interact with transmembrane ligands on adjacent cells. 
The mammalian genome encodes four receptors (Notch 1-4) and five ligands (Delta-
like-1, -3, -4 and Jagged-1 and -2). Ligand engagement initiates a process called 
“regulated intramembrane proteolysis” (RIP), in which the Notch receptor is first 
cleaved at a juxtamembrane extracellular site by a mettalloprotease of the ADAM (a 
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disintegrin and metalloprotease) family. This cleavage renders the truncated receptor 
sensitive to subsequent intramembrane cleavage(s) by the γ-secretase multiprotein 
enzyme complex. Processing by γ-secretase releases the Notch intracellular domain 
(NICD) from the membrane, allowing it to translocate into the nucleus where it 
assembles into a trascriptional activation complex that permits the expression of 
Notch-responsive genes such as Hes. Components of this complex are DNA-binding 
trascription factor CSL (C-promoter-binding factor, also known as RBP-J) and co-
activator such as protein of the Mastermind (MAM) family (Figure 8). NICD comprises 
several functional regions, including an N-terminal RBP-Jk (recombination binding 
protein-jk-associated molecule) domain, a unique negative regulatory region (NRR), 
an ANK (ankyrin repeat) domain and less-conserved regions including a variable 
transactivation domain and a C-terminal PEST (Pro-Glu-Ser-Thr) sequence; the ANK 
domain is essential for the folding and for the function of NICD and it can render CSL 
competent for MAML loading; the RAM region is necessary to recruite NICD and the 
PEST domain is involved in NICD turnover. The extracellular domain (ECD) of Notch, 
contains between 29 and 36 tandem repeats of EGF domains (epidermal growth 
factor-like domains), that can be modified by three different types of O-linked 
glycosylation: O-fucosylation, O-glucosylation, and O-GlcNAc’ylation115-116. The best 
characterized modification is the O-fucosylation, that is catalyzed by an O-
fucosyltransferase (Pofut1 in mammals and Ofut1 in Drosophila) that uses GDP-
fucose as a substrate. There are two models proposed to elucided the role of Ofut1: 
the first model proposes that Ofut1 acts in the endoplasmic reticulum, where it 
performs two separable functions: to O-fucosylate Notch, thereby modulating Notch-
ligand interaction, and to promote the correct folding of the extracellular domain of 
Notch (a non-catalytic function). The second model proposes that Ofut1 is required 
for secretion of Notch117. The O-fucose residue added by Pofut1 can be further 
elongated by the addition of an N-acetylglucosamine by Fringe, an EGF-O-fucose 
β1.3 N acetylglucosamyltransferase. The Notch signaling requires regulation by 
Fringe glycosyltransferases that determine which ligands can bind to activate the 
receptor. Infact, Fringe potentiates the activation of Notch by Delta and inhibits 
activation by Serrate in a cell-autonomous manner118. This ligand specificity switch is 
employed in stage- and tissue-specific regulation of Notch signaling to establish 
tissue boundaries during animal development119. Particularly, in mammals, 
elucidation of the effects of Fringe on Notch activity is complicated by the presence of 
multiple receptors, ligands, and Fringe proteins (Lfng, Lunatic fringe; Mfng, Manic 
fringe and Rfng, Radical fringe). Notch signaling can be regulated by endocytosis; 
NICD becomes monoubiquitylated (Ub), targeting the receptor to the lysosome for 
degradation. The first evidence that Notch signaling plays a role in cell-type 
specification in the intestine was reported in Hes1 knockout mice120. The deletion of 
the Hes1 gene resulted in the generation of excessive numbers of goblet cells, 
enteroendocrine cells, and Paneth cells, all of which possess a secretory 
character121. Subsequently, it was shown that the gene encoding another bHLH 
factor, Math1 (mouse atonal homolog1), one of the genes repressed by Hes1, is 
required for the differentiation into the three secretory lineages, because the 
intestinal epithelium of Math1-mutant mice is populated only by absorptive cells121. 
These data suggest that the choice between the absorptive or secretory fate might 
be the first decision made by each progenitor cell, and that Hes1 and Math1 play 
opposite roles in this decision making105,121-122. While the specification of precursors 
into enterocyte fate is determined by Hes1, the differentiation of secretory precursors 
into goblet or endocrine fate is regulated by Math1; it has been shown that the choice 
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Figure 8. The canonical Notch signalling pathway.  
(From Nature Review Immunology, 2009). 
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of lineage commitment among the Math1-specified secretory cell types123 is 
controlled by several other transcriptional regulators124 such as NeuroD3 
(neurogenin3 for enteroendocrine cell differentiation)125, KLF-4 (Kruppel-like factor-4 
for goblet cell differentiation)126 or Gfi 1 (for goblet/Paneth cells differentiation)127. 
These studies are of considerable importance for understanding the stepwise 
regulation of the differentiation into each lineage of epithelial cells and for clarifying 
the molecular hierarchy during this process105. Another direct genetic evidence 
showing an essential role of Notch signaling in the intestinal homeostasis, is derived 
from inducible tissue specific inactivation of CSL/RBP-J. Loss of CSL/RBP-J within 
the crypt compartment leads to a complete loss of proliferating transient amplifying 
cells followed by their conversion into postmitotic goblet cells111. Conversely, 
expression of NICD in the gut inhibits differentiation of crypt progenitor cells resulting 
in an intestine that largely consists of undifferentiated transient amplifying cells128. 
These complementary loss- and gain-of-function studies suggest that Notch signaling 
is a gatekeeper of the progenitor/stem cell compartment of the gut97. In addition, 
blocking of all Notch/ligand interaction by targeted inactivation of the Pofut1 gene in 
mouse small intestinal and colonic epithelia enhanced the commitment of crypt 
progenitor cells toward secretory cell lineages, and leads to hypersecretion of mucus, 
modification of the gut microbiota and development of intestinal inflammation122. 
Additional evidence is derived from toxicology studies of γ-secretase inhibitors. 
These small molecules are currently being developed by pharmaceutical companies 
to inhibit the protease (γ-secretase) activity of presenilins for the treatment of 
Alzheimer’s disease. The primary target of these drugs is the disease causing 
amyloid precursor protein (APP). The treatment with γ-secretase inhibitors in mouse 
models for Alzheimer’s disease displays unwanted side effects such as a large 
increase in mucus secreting goblet cells129 and in Han Wistar rats, goblet cell 
metaplasia130 both due to inhibition of Notch signaling. Taken together these results 
suggest that Notch signaling is essential for maintenance of undifferentiated crypt 
progenitors. In this respect the Notch and Wnt signaling pathways appear to work 
hand in hand. Loss of either signaling cascade results in loss of the crypt 
compartment (Figure 9). In addition to the classic functions of Notch in regulating 
development and cell fate selection, new insights into an ongoing role of Notch in 
lymphocyte function are emerging that are relevant to the gut. These studies reveal 
that Notch signaling can regulate T-cell receptor-mediated T-cell proliferation and 
apoptosis, development of Th1/Th2 immune responses, and the decision between 
immunity and tolerance. 
 
- TGF-/BMP pathway 
The TGF-β superfamily consists of a number of secreted cytokines including different 
TGF-β isoforms (TGFβ 1, TGFβ 2, and TGFβ 3), BMPs and activins. 
These proteins are known to regulate a broad spectrum of different processes such 
as embryonic development, differentiation, proliferation, adhesion, wound healing  
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Figure 9. Cell fate specification within the intestine and involvement of Wnt and 
Notch signalling pathways. 
(From Current Molecular Medicine, 2006) 
.
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and inflammation131-132. The activated TGF-β mediates its effects on cells through 
heteromeric complexes of TGF-β type I and II (TβRI and TβRII) receptors to activate 
intracellular signaling pathways, including Smad signaling. The resulting Smad 
complex then moves into the nucleus, where it interacts in a cell specific manner with 
various transcription factors to regulate the transcription of many genes133. 
Deregulation of the TGF-β signaling can occur at multiple levels of the pathway, and 
the cancer-related alterations frequently appear to promote progression of tumors. In 
normal cells, TGF-β induces differentiation or promotes apoptosis because it arrests 
the cell cycle at the G1 stage to inhibit proliferation, acting as a tumor suppressor. 
The immunosuppressive cytokine TGF-β is abundantly expressed in the gut and 
plays an important role in maintaining immune homeostasis. TGF-β is produced by 
both stroma and T cells in the gut; in contrast to signaling components of Wnt and 
Notch pathways, which are localized to the undifferentiated crypt, TGF-β receptor 
and ligands, are expressed in the differentiated compartment of the gut. In addition to 
its immunosuppressive properties, TGF-β is also a critical factor for IgA class 
switching that helps generating the IgA-predominated immunoglobulin milieu 
characteristic to the intestine. In the intestine, the BMP pathway is seen most 
strongly in the epithelium of the villi, whereas noggin, the BMP antagonist, is 
expressed in the neighbourhood of the crypts. When the receptor is knocked out, or 
the antagonist noggin is overexpressed, excessive quantities of cryptlike structures 
develop: in the noggin overexpression mutant, these occur on the sides of the villi134; 
in the mouse Bmpr1a knockout, there is also a marked increase in the number of 
crypts in the region within which crypts normally lie135. Similar abnormalities are seen 
in humans with juvenile polyposis syndrome, which can be traced to mutations in 
BMPR1A or SMAD4 (a key downstream effector of BMP signalling). All this evidence 
strongly suggests that BMP signalling is a key factor that blocks the formation of 
ectopic crypts, mediating the action of hedgehog, and that the expression of noggin 
in the neighbourhood of each crypt base protects the epithelium in this region from 
the action of BMPs, thereby enabling proliferation to continue136. 
 
- Hedgehog pathway 
The Hedgehog (Hh) signalling pathway was originally described in the development 
of Drosophila melanogaster as a segment polarity gene required for embryonic 
patterning. There are 3 vertebrate homologues of Hh: Sonic hedgehog (Shh), Indian 
hedgehog (Ihh) and Desert hedgehog (Dhh). The Hedgehog signal is transmitted by 
a seven-span transmembrane receptor Smoothened (Smo). Interestingly, 
Hedgehogs do not bind to Smo but control the activity of Smo indirectly by binding to 
a second receptor, Patched (Ptc) that acts in a negative-feedback loop to restrict the 
range of Hedgehog signaling in a tissue137. This pathway is responsible for several 
relatively common congenital malformations such as tracheoesophageal fistula and 
anorectal malformations. The Hh signaling pathway has an established role in growth 
and patterning during embryonic development of the gastrointestinal tract, when both 
Sonic hedgehog and Indian hedgehog are expressed by the endoderm throughout 
the gut tube138. Infact, in the small intestine, both Shh and Ihh are produced only in 
those sites at which proliferation persists: the intervillus pockets and subsequently 
the bases of the crypts. The suggestion, therefore, is that hedgehog proteins diffuse 
outwards from these sites and exert their effect at a distance, promoting villous 
formation and inhibiting crypt-like behaviour in the neighbourhood of each 
established crypt. In the colon Hh signalling is strongly implicated in directing 
enterocyte differentiation139. Infact, constitutive activation of Hh signaling resulted in 
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accumulation of myofibroblasts and colonic crypt hypoplasia. A reduction in the 
number of epithelial precursor cells was observed with premature development into 
the enterocyte lineage and inhibition of Wnt signaling. Activation of Hh signaling 
resulted in induction of an increased BMP signaling in the epithelium138. 
Conversively, blocking of the hedgehog signal by strong overexpression of an 
inhibitor, hedgehog-interacting protein (HHIP), leads to a complete absence of villi 
and the persistence of a highly proliferative, and sometimes pseudostratified, 
intestinal epithelium, with increased activation of the Wnt pathway and a deficit of 
properly differentiated cells140. The general conclusion is that hedgehog signalling 
from epithelium to mesenchyme is required for the formation of villi and the 
concomitant restriction of proliferation to the intervillus regions within the intestinal 
epithelium. This process must depend on a feedback loop in which mesenchymal 
cells respond directly to hedgehog from the epithelium, and deliver a signal back to 
the epithelium by some other signalling pathway136. 
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AIMS OF THIS PROJECT 
 
Epigenetics is becoming important in several fields, also in the field of nutritional 
genomics, which try to fill fundamental gaps in the knowledge of nutrient-genome 
interactions in health and disease. For example, human epidemiologic studies as well 
as increasing animal models demonstrate that maternal nutrition can “programme” 
gene expression patterns in the embryo that persist into adulthood and contribute to 
metabolic disease141. So, epigenetic mechanisms may provide a possible 
explanation for how environmental influences in early life cause long-term changes in 
disease susceptibility. Further, among a variety of epigenetic factors, essential 
nutrients, but also environmental toxins, have been show to affect epigenetic 
mechanisms, such as DNA methylation, modification of histone proteins and RNA 
silencer pathway. It is evident that the potentially reversible epigenetic 
dysregulations, for example involving miRNAs, may also have an important role in 
the disease origin, such as CD. 
The aim of this project is to perform an extensive study of the different miRNAs 
expression pattern in intestinal mucosa from celiac patients at different stages of the 
disease (with active CD and at gluten free diet) and from controls, to investigate the 
role of these molecules in transcriptional regulation in CD.  
The identification of miRNAs differently expressed in CD patients respect to controls 
will allow to identify their gene target and the metabolic pathways that could be 
involved in the disease insurgence. Particularly, the identification of miRNAs 
expressed differently only in active CD vs remitted CD, could identify genes involved 
in mucosal inflammation; the miRNAs expressed similar in CD and in GFD patients 
vs controls, could identify genes involved in pathogenesis of CD. So, these results 
could contribute to explain molecular mechanisms involved in CD pathogenesis. 
Deeper understanding of miRNAs mechanism in health and CD, their relationship 
with the environmental influences and the way they are associated with the disease 
phenotype, may lead to development of new biomarkers and new appropriate 
therapeutic strategies. Infact, it can clarify molecular mechanisms involved in 
pathogenesis of CD and can drive new terapeuthical approach based on miRNA-
oligonucleotides. For example, miRNAs differently expressed in CD and in GFD 
patients vs controls, can be used as genetic marker to identified precociously CD in 
risk subjects (subjects with clinical suspicious of CD, but with normal mucosal 
architecture, and first grade parents). 
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MATERIALS AND METHODS 
 
Patients and controls  
We recruited 20 children with suspected CD, 9 undergoing CD follow-up and 15 
controls, among patients consecutively attending the Department of Paediatrics and 
the European Laboratory for the Investigation of food-induced diseases (ELFID) of 
the University of Naples “Federico II”. From all patients and controls, we collected a 
fasting serum sample, a blood sample with EDTA, and a small intestinal bioptic 
sample.  
The general characteristics of the celiac patients and control children are reported in 
Table 2. The 55% of CD patients were girls and the age at diagnosis was 4.3±1.3 
(mean±SEM) years. The 80% of these had gastrointestinal symptoms; the 85% of 
active CD (17/20) had a villous atrophy classified as TIIIC according to the modified 
Marsh classification; instead, the remaining 15% (3/20) had a villous atrophy 
classified as TIIIB. All active CD children were positive for tTG or EMA (IgA); only 1 
subject was negative for these antibodies but was positive for both AGA IgG/IgA 
antibodies. The control patients were 15 and the 45% of these were girls; they were 
not-CD age-matched because the age at diagnosis was 6.1±1.0 (mean±SEM) years. 
Control subjects also underwent histological examination of the small intestine, even 
if they were negative for serum autoimmune markers, in order to confirm the 
diagnosis or to rule out the silent form of CD. Eleven of the 15 control patients were 
enrolled in the study with one of the following final diagnoses: Helicobacter pylori 
infection, recurrent vomiting, lack of appetite or reflux esophagitis. The remaining 4 
patients were affected by IgA deficit (2 cases), De George syndrome (1 case) and 
autoimmune thyroiditis (1 case), and were excluded from the study because 
considered potentially confounding diseases. All control subjects had slight or no 
abnormalities in the mucosal architecture: infact, the 64% of these (7/11) has normal 
mucosal architecture classified as type T0-Marsh stage, but the remaining 36% 
(4/11) revelead normal mucosal architecture in which the villous epithelium was 
markedly infiltrated by lymphocytes (TI Marsh stage). The 9 GFD patients had been 
on a GFD for at least 2 years; infact, the histological examination of the small 
intestine carried out after 2 years of free-gluten diet, revelead normal mucosal 
architecture; the 55% of these (5/9) were girls and the age at diagnosis was 7.6±2.5 
(mean±SEM) years. Written informed consent was obtained from all individuals 
before their enrollment. The study was conducted according to the Helsinki II 
declaration and it was approved by the Ethics Committee of our School of Medicine.  
 
Biochemical parameters 
A fasting serum sample was used to evaluete the biochemical parameters. Anti-
Endomysium IgA were detected by indirect immunofluorescence microscopy on 
rhesus monkey esophagus substrate (Eurospital, Trieste, Italy); tTG IgA, anti-gliadin 
(AGA) IgA/IgG were analyzed by ELISA with human recombinant tTG as antigen 
(DIA Medix Corp., Miami, FL, USA). IgA deficiency was evalueted using a 
nephelometric assay (DADE BEHRING, BNProSpec) in all subjects negative for CD 
antibodies.  
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Table 2. General characteristics of studied celiac patients (active CD and GFD 
subjects) and control children (CTRL) 
 
 
a
 Data are expressed as percentage (%) or as mean ± standard error of the mean 
(SEM) 
b
 At gluten free diet from at least 2 years  
c According to Marsh classification 
d Only 1 subject was negative for these antibodies but was positive for both AGA 
IgG/IgA antibodies 
 
Characteristicsa Subjects 
  Active CD 
(n=20) 
GFDb 
(n=9) 
CTRL 
(n=11) 
Sex Female (%) 55 55 45 
Age (years) 4.3 ±1.3 7.6 ± 2.5 6.1 ± 1.0 
Clinical presentation:    
                    Gastrointestinal symptoms (%) 80 22 82 
                    Villous atrophy % (Marsh stage)c TIIIB 15 
TIIIC 85 
T0 56 
TI 44 
T0 64 
TI 36 
                    Positive tTG or EMA (IgA) d  19 3 0 
Familiarity for:    
                     CD (%) 20 22 0 
                     Other autoimmune diseases (%) 5 11 0 
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DNA extraction  
Genomic DNA was extracted from a blood sample plus EDTA using the Nucleon 
BACC 2 kit (Amersham Biosciences Europe, Milan, Italy). The DNA was dissolved in 
water; the final DNA concentration and purity was measured using a NanoDrop ND-
1000 spectrophotometer (NanoDrop technologies, Wilmington, DE, USA). The 
agarose gel electrophoresis was used to determine the success of the extraction and 
to evaluate the amount of high molecular weight nucleic acids and eventually its 
degradation (see “electrophoresis” section). The purified DNA was storage at -
20°C. 
 
HLA typing  
DQ2/DQ8 HLA susceptibility molecules were identified using specific primer-PCR 
typing of the HLA-DQA1*/DQB1*/DRB1* loci (BAG Health care GmbH, Lich 
Germany). This kit uses Sequence Specific Primers (SSP)-PCR to detect specific 
HLA genotype. Infact, the kit consists of a 24 wells-plate, in which are deposited the 
prealiquoted and dried reaction mixtures for both DQ2/DQ8 alleles specific primers 
and internal control primers (specific for the human G3PDH gene). Ten µl of Master-
Mix [consisting of 10X PCR-buffer, 50 µl DNA (50 ng/µl), 1 ul Taq-Polymerase (5U/µl) 
and H2O] were added to pre-dropped reaction mixtures. The plate was put on a 
thermal cycler and the PCR program was the following: 1x (5’at 96°C); 5x (20”at 
96°C, 1’at 68°C); 10x (20”at 96°C, 50”at 64°C, 45”at 72°C); 15x ( 20”at 96°C, 50”at 
61°C, 45”at 72 °C); 1x (5’at 72°C). The amplification products were separated by 
electrophoresis agarose gel and the results were interpretated using the specific 
software (see “electrophoresis” section). 
 
Electrophoresis 
Agarose gel electrophoresis is a method that separates a mixed population of nucleic 
acids (DNA and RNA) fragments by length, to estimate their size. Nucleic acid 
molecules are separated by applying an electric field to move the negatively charged 
molecules through an agarose matrix. Shorter molecules move and migrate faster 
than longer ones because shorter molecules migrate more easily through the pores 
of the gel. Agar or agar-agar is a gelatinous substance derived from a polysaccharide 
that accumulates in the cell walls of agarophyte red algae. The gel concentration 
used to separate SSP-PCR products was 2.0% (2 gr of agarose in 100ml 1X TBE), 
but to evaluete DNA purity was 1% (1 gr of agarose in 100ml 1X TBE); the agarose 
solution was boiled to dissolve the agarose and then was added 5 µl ethidium 
bromide stock (10 mg/ml) for a final concentration of 0.5 µg/ml. The ethidium bromide 
is a common dye used to make nucleic acids bands visible because it fluoresces 
under UV light when intercalated into DNA or RNA. The solution was stired to 
disperse the ethidium bromide and then it was poured into the gel rack. When the gel 
has cooled down and become solid, it was puted into a tank with the electrophoresis 
buffer 0.5X TBE (45 mM of tris, 45 mM of boric acid, 0.5 mM of EDTA). The PCR 
mixtures were loaded with 2 µl 6X loading buffer (0.25% w/v bromophenol blue, 30% 
glycerol and 0.25% w/v xylene cianol) in each slot of the gel; in addition, 10 µl of the 
DNA length standard for size comparison [Marker XVI Roche (0.25-3.090 kbp)] was 
loaded into a well. Electrophoretic separation was done at 100 V/cm, for 20-40 
minutes. After the run has been completed, the DNA bands were visualized on a UV 
transilluminator. The gel can then be photographed with a polaroid camera. 
Particularly, to detect the overall quality of an RNA preparation it was preferred the 
electrophoresis on a denaturing agarose gel: the RNA was denaturated for 5 min at 
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94°C and then it was loaded on the gel; the electrophoresis was performed at 50 
V/cm and then the RNA was visualized on a UV transilluminator.  
 
Histopathological analysis 
Biopsy specimens from the distal duodenum were obtained by upper gastrointestinal 
endoscopy from all CD patients and controls enrolled in this study; each bioptic 
sample was divided in two aliquots: one was used to histopathological analysis and 
the other was frozen in liquid nitrogen to RNA extraction.  
 
RNA extraction 
Total RNA, including miRNAs, was extracted from an aliquot of bioptyc samples for 
each patient, using the Mirvana extraction kit (Applied Biosystems, Foster City, CA, 
USA). Each frozen biopsy has been removed from -80°C freezer and immediately 
processed to evoid that ice crystals could rupture cellular compartments, releasing 
RNases.  
The extraction was performed in 3 steps: 
- Tissue lysis  
The weight of the bioptyc sample was measured and then was added 10 volumes of 
lysis/binding buffer per tissue mass to preserve RNA; then the sample was 
homogenate using a tissue lyser system (Tissue Lyser II-Retsch Quiagen) using 
beads of 3 mm diameter, for 2 minutes at 18 oscillations for second 
- Organic extraction 
At the homogenate sample was added 1/10 volume of miRNA homogenate Additive 
and then the mixture was leaved on ice for 10 minutes; then it was added a volume 
of acid-phenol:Chloroform to remove proteins and cellular residues; the mixture was 
vortexed for 1 minute and then was centrifugated for 5 minutes at 10.000 g at room 
temperature. The upper phase was transferred into a fresh tube. 
- Isolation of total RNA including miRNAs 
At the sample was added 1.25 volumes of room temperature 100% ethanol and then 
it was loaded onto a filter; it was centrifugated for 15 seconds at 10.000 g to pass the 
mixture through the filter, and then the filter was washed with 2 differently solutions; 
the filter was trasfered into a fresh tube, it was applyied 100µl of pre-heated water 
(95°C) and then was centrifugated at 10.000 g for 30 seconds to elute the total RNA. 
The final RNA concentration was measured using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). The agarose gel electrophoresis was 
used to evaluate the amount of high molecular weight nucleic acids and eventually its 
degradation, because the RNA purity and integrity were critical factors for the real-
time PCR (see “electrophoresis” section). The purified RNA was storage at -80°C. 
 
TaqMan Low Density Array (TLDA) technology 
The TaqMan Low Density Array (TLDA) is an efficient and flexible technology that 
enables real-time PCR in a low-density array format and streamline gene expression 
using ABI PRISM 7900HT Sequence Detection System. TLDA are 384-well micro 
fluidic cards, pre-loaded with real-time PCR assays available for human, mouse, and 
rat gene. This technology is used to obtain a miRNA profiling because it selectively 
detect and quantify the mature, biologically active form of miRNAs; infact, TLDA 
takes advantage of a novel reverse transcription step utilizing unique hairpin-loop RT 
primers that are specific to only the mature miRNA species. Infact, the design of a 
random-primer RT is prohibited for the short length of mature miRNAs (~22 
nucleotides), but the stem-loop structure provides specificity for only the mature 
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miRNA target and forms an RT primer/mature miRNA chimera that extends the 3’ 
end of the miRNA. The resulting longer RT amplicon presents a template amenable 
to standard real-time PCR using TaqMan Assays. It can also discriminate between 
highly homologous targets (http://mirna.appliedbiosystems.com). The TLDA used 
(Human MicroRNA Array v1.0) contains 365 different human miRNA assays in 
addition to two carefully selected small nucleolar RNAs (snoRNAs: RNU48 and 
RNU44) that function as endogenous controls for data normalization (Figure 10). 
Usually, the amplification of an endogenous control is performed to standardize the 
amount of RNA sample. Our normalization was performed using as endogenous 
control the RNU48 because its expression was relatively constant in all studied 
intestinal samples. 
The TaqMan Array is designed for two-step RT-PCR: 
1) In the reverse-transcription (RT) step, cDNA is reverse transcribed from total 
RNA samples (800 ng).  
2)  In the PCR step, PCR products are amplified from cDNA. 
Particularly, an equivalent amount of RNA into RT reaction and an equivalent volume 
of the cDNA for the real-time PCR reactions were used. All 365 miRNA targets were 
reverse transcribed in eight separate RT reactions for the 8 fill ports present in each 
card; the components used to prepare the RT-Mix are described in Table 3 and the 
termal cycler’ program used for RT-PCR are reported in Table 4. The eight 
predefined RT primer pools were a mixture containing up to 48 RT primers each. A 
total of eight independent RT reactions were run for sample. After the RT-PCR, the 8 
RT reactions were diluited and 8 RT Master Mix was prepared as described in Table 
5. Each RT Master Mix was pipetted into the corresponding filling ports on the 
TaqMan Array. The loaded card was centrifugated 2 times at 1200 rpm for 1 min to 
obtain a complete distribution of PCR reaction mix in the multiple wells; then it was 
sealed to prevent well-to-well contamination and the fill consumable was trimmed off.  
Finally, the cards were processed on an ABI Prism 7900 HT apparatus (Applied 
Biosystems) using the thermal cycler conditions described in Table 6.  
 
SDS Software Plate Documents 
Each TLDA was supplied of SDS plate documents contained information necessary 
to run the card on the 7900HT instrument because it configured the plate document 
plate grid and setup table. Then, SDS plate documents stored data collected from a 
run including sample names and detectors. The fluorescence data generated in this 
step were elaborated with System Relative Quantitation software 2.3 to determine 
relative levels of miRNAs expression. 
 
Comparative C
T 
Method (∆∆Ct) and SDS Version 2.3 Software 
SDS Version 2.3 Software delivers a complete suite of tools to perform the ∆∆CT 
calculations in addition to real-time PCR plate set-up and analysis of gene 
expression, pathogens, and SNPs (www.7900ht.com). This software analyzes 
fluorescence data generated during PCR for each card using Comparative CT 
method (∆∆CT) that is a convenient method to analyze the relative changes in gene 
expression. The ∆∆CT Method is similar to the Relative Standard Curve Method, 
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Figure 10 .TaqMan
 
Low Density Array Human MicroRNA Panel v1.0 (A) Each TLDA 
Human MicroRNA Panel v1.0 card contains 365 preloaded human miRNA targets, 
endogenous controls (underlined in red) and negative controls (underlined in blue). 
(B) Cards structure. 
 
A 
B 
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Table3. Components used to prepare the RT-Mix; the final volume for each RT 
reaction is 10 µL. 
 
 
 
 
Table 4. The termal cycler’ program used to Multiplex Reverse Transcription-
PCR (RT-PCR). 
 
 
 
 
 
 
 
 
 
 
 
Table 5. The components used to prepare the RT Master Mix. 
 
 
 
 
 
 
 
 
 
Table 6. Thermal cycler conditions used to process the cards on a 7900HT 
Fast Real-Time apparatus (Applied Biosystems). 
 
Component Volume (µL) for 1 RT 
reaction 
100 mM dNTPs (with dTTP) 0.20 
MultiScribe Reverse Transcriptase, 50 U/mL 2.00 
10X Reverse Transcription (RT) Buffer 1.00 
RNase Inhibitor, 20 U/µL 0.125 
Total RNA (800 ng) 2.00 
Multiplex RT Human primer pool 1.00 
Nuclease-free water 3.675 
Step Type Time (min) Temperature (°C) 
HOLD 1 30 16 
HOLD 2 30 42 
HOLD 3 5 85 
HOLD 4 ∞ 4 
Component Volume (µL) for 
reaction 
Diluted RT Reaction (10 µL RT-PCR+ 615 µL H2O) 50.0 
TaqMan Universal PCR Master Mix (2X) 50.0 
Total Volume 100.0 
Step Type Time (min) Temperature (°C) 
HOLD 1 2 50 
10 94.5 
0.5 97 HOLD 2    (40 cycles) 
1 60 
HOLD 3 ∞ 4 
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except it uses arithmetic formulas to achieve the result for relative quantitation.  
It is possible to eliminate the use of standard curves and to use the ∆∆CT Method for 
relative quantitation as long as the PCR efficiencies between the target(s) and 
endogenous control(s) are relatively equivalent. This method is useful when a high 
number of targets and/or number of samples are tested; infact, the standard curves 
are not required to run on each plate. It requires the assignment of one or more 
housekeeping genes (endogenous controls), which are assumed to be uniformly and 
constantly expressed in all samples, as well as one or more reference samples. 
Because the endogenous control is used to normalize differences in the amount of 
cDNA that is loaded into PCR reaction wells, endogenous control expression levels 
must be similar in all samples in the study (while the target’s expression levels may 
vary widely, expression of the endogenous control remains constant). The 
endogenous sample used in this study was RNU48 because it observed this feature. 
The fold-differences in miRNAs expression are first determined from the threshold 
cycle (CT) values normalized to the expression of the reference sample. The CT 
indicates the fractional cycle number at which the amount of amplified target reaches 
a fixed threshold. The expression of other samples is then compared to that in the 
reference sample. The amount of target, normalized to an endogenous reference and 
relative to a calibrator, is given by 2-∆∆CT. The ∆CT value is calculated by: ∆CT=CT 
target-CT reference. The ∆∆CT is calculated by: ∆∆CT=∆CT test sample-∆CT calibrator 
sample. The calibrator is a sample that is used as the basis for comparative 
expression results. In this study the calibrator was a mean of fluorescence data 
obtained from controls. So, the RQ of each miRNA calculated with the 2-∆∆CT 
algorithm represented, in this study, the miRNA fold change expression level 
measured in CD patients vs the mean level obtained in the controls. We considered 
differently expressed in CD patients vs control, the miRNAs whose mean RQ levels 
were ≤0.5 (downregulated) or ≥2.0 (upregulated) in almost 15/20 active CD (75%) 
and 7/9 GFD patients (78%). The RQ levels were expressed as mean±standard error 
of the mean (SEM) between 3 study groups (active CD and GFD patients vs control 
subjects).  
 
TaqMan chemistry 
After the reverse transcription, the PCR is performed using MGB probe; the TaqMan 
MGB probes contain a reporter dye (6-FAM™ dye) linked to the 5´ end of the probe, 
a minor groove binder (MGB) and a non fluorescent quencher (NFQ) at the 3´ end of 
the probe. MGBs increase the melting temperature (Tm) without increasing probe 
length142; they also allow the design of shorter probes.  
Briefly, during PCR each TaqMan MGB probe anneals specifically to its 
complementary sequence between the forward and reverse primer sites; when the 
oligonucleotide probe is intact, the proximity of the quencher dye to the reporter dye 
causes the reporter dye signal to be quenched. A DNA polymerase extends the 
primers bound to the cDNA and (a 5´nuclease) cleaves the probes that are 
hybridized to the target sequence; when the hybridized probes are cleaved by 
enzyme, the quencher is separated from the reporter dye, increasing the 
fluorescence of the reporter dye.  
Therefore, the fluorescence signal generated by PCR amplification indicates the 
gene expression level in the sample. 
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Bioinformatic prediction of target genes for miRNAs 
Computational algorithms for target prediction in mammals combine base pairing 
pattern, thermodynamic stability of miRNA-mRNA hybrid, comparative sequence 
analysis to check conservation and examination of the presence of multiple site, in 
order to maximize specificity. To determine possible target genes for the differentially 
expressed miRNAs in celiac disease, we used miRecords 
(http://mirecords.biolead.org/). MiRecords is an integration of 11 established miRNA 
target prediction programs: DIANA-microT, MicroInspector, miRanda, MirTarget2, 
miTarget, NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and 
TargetScan/TargertScanS. We considered only the target genes predicted by two or 
more programs of Mirecords; particularly, based on literature data, we considered 
preferentially, TargetScan, PicTar and Miranda. TargetScan 
(http://www.targetscan.org/) is an algorithm that identified the targets of vertebrate 
miRNAs. The program integrates thermodynamics-based modeling of miRNA-mRNA 
interactions and comparative sequence analysis to predict miRNA targets conserved 
across multiple genomes such as human, mouse and rat. It searches for seed 
matches in the first organism such as human and expand each seed match with 
additional base pairings to the miRNA. The thermodynamic properties of miRNA-
mRNA duplexes are assessed by calculating free-energy (∆G) of the putative binding 
site by using the RNAFold package (http://www.tbi.univie.ac.at/~ivo/RNA/) and 
assign a score to each UTR. This is very important because allow to identify complex 
RNA secondary structures located in the 3’UTR that may prevent miRNA/mRNA 
interactions; in fact, a common feature of most validated targets is that miRNAs 
preferentially target 3’-UTR sites that do not have complex secondary structures and 
are located in accessible regions of the mRNA based on favourable thermodynamics. 
Moreover, a low free energy of hybridization does not guarantee accurate prediction 
of miRNA target genes143, thus, it is inevitable to consider additional features such as 
conservation analysis for reliable prediction of target transcript. Contrary to 
TargetScan that require a seed match at exactly corresponding positions in a cross-
species UTR alignment, PicTar requires binding sites that are coregulated by multiple 
miRNAs across species; infact, multiple copies of miRNA target sites on the 3′ UTR 
of the gene in question increase the degree of translational suppression and enhance 
specificity of gene regulation. In detail, PicTar checks the alignments of 3' UTRs for 
those displaying seed matches to miRNAs, filters the retained alignments based on 
their thermodynamic stability, and computes a hidden Markov model (HMM) 
maximum likelihood score (PicTar score) for each predicted target. To filter out false 
positives, PicTar used statistical tests based on genome-wide alignments of eight 
vertebrate genomes and considered clustering co-expressed miRNAs and matching 
miRNAs with putative targets that are expressed in the same context. Finally, 
MiRanda selected target genes for each miRNA, on the basis of three properties: 
sequence complementarity using a position-weighted local alignment algorithm, free 
energies of RNA-RNA duplexes, and conservation of target sites in related genomes. 
Infact, evolutionary conservation is another important factor to filter out false positive 
targets and increase specificity. It helps to predict only the target sites which are 
under selective pressure to preserve their sequence and presumably functionality, 
across evolution. The genes predicted by two or more programs of Mirecords, were 
then combined and analyzed using WebGestalt (WEB-based GEne SeT AnaLysis 
Toolkit) (http://bioinfo.vanderbilt.edu/webgestalt/). It is designed for functional 
genomic, proteomic and large-scale genetic studies from which large number of gene 
lists (e.g. differentially expressed gene sets, co-expressed gene sets etc) are 
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continuously generated. WebGestalt incorporates information from different public 
resources and provides an easy way to make sense out of gene lists. Particularly, in 
this study we used Gene Ontology Tree Machine (GOTM) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database. GOTM (http://bioinfo.vanderbilt.edu/gotm/) 
is a web-based tool for the analysis and visualization of sets of interesting genes 
based on Gene Ontology hierarchies. It provides statistical analysis to indicate GO 
categories with relatively enriched gene numbers and suggest biological areas that 
warrant further study. Enriched GO categories can be visualized in Sub-trees or 
DAGs. Subset of genes can be retrieved by GO term or keyword searching. 
WebGestalt can organize genes based KEGG database 
(http://www.genome.ad.jp/kegg/) that is an integrated database resource consisting 
of 16 main databases, broadly categorized into systems, genomic and chemical 
informations. In detail, it shows KEGG pathways associated with the gene set, the 
number of genes in each pathway and the Entrez Gene IDs for the genes. It also 
provides P-values, indicating the significance of enrichment for each KEGG pathway. 
Each KEGG pathway is hyperlinked to the KEGG Map, in which genes in the gene 
set are highlighted in red. However, because a perfect seed pairing may not 
necessarily be a reliable predictor for miRNA interactions144, targets for miRNAs 
remain to be identified or verified experimentally.  
 
The Reverse Transcription-PCR (RT-PCR)  
The RT-PCR was performed for each RNA sample in order to obtain the cDNA to 
perform a qRT-PCR both for miR-449a and for NOTCH1 and HES1 mRNAs. For the 
very small quantity of total RNA obtained by little bioptic samples, the RT-PCR was 
performed using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) that yields very quantitative amplification of total RNA from 0.02 to 2 µg. 
Two aliquot of total RNA from each sample were reverse transcribed (RT) both with a 
miRNA-specific stem-loop primer (for miRNA assay) and with a random primers (for 
mRNA assay) following the manufacturer's protocol. The RT master mix was 
prepared in ice, as reported in Table 7 and then loaded into the thermal cycler, using 
the program reported in Table 8. The cDNA was storage at -20°C and then used to 
perform the qRT-PCR. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) of miRNAs and 
mRNAs 
To confirm the high level of miR-449a in small intestinal biopsy evalueted by TLDA, a 
qRT-PCR was performed with TaqMan microRNA assays (Assay ID: 001030 Applied 
Biosystems) in accordance with the manufacturer’s instructions. This assay is used 
to quantify and to detect the profile of a specific miRNA. It can also distinguish 
between highly homologous targets; infact, because many miRNA family members 
differ in sequence by as little as one base, real-time PCR using TaqMan helps 
provide the specificity needed for differentiation. Moreover, it takes advantage of a 
novel reverse transcription step utilizing unique hairpin-loop RT as described in TLDA 
section. The mRNA expression levels of NOTCH1 and of HES1 were measured in 
small intestinal tissues by qRT-PCR using single TaqMan gene expression assays 
(respectively Assay ID: Hs01062011_m1 and Hs00172878_m1 Applied Biosystems) 
in accordance with the manufacturer’s. During the target amplification step, the 
AmpliTaq Gold DNA polymerase was used to amplify target cDNA synthesized from 
the RNA sample, using sequence-specific primers both for miR-449a and NOTCH1 
and HES1 mRNA. The PCR reaction was prepared in ice (the components are  
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Table 7. Components used to prepare the RT-Master Mix both for mRNA (A) and for 
miRNA (B) RT-PCR. 
 
Components 
(A) 
Volume (µL) for 
1reaction (20µL) 
(B) 
Volume (µL) for 
 1 reaction (15µL) 
10X RT buffer 2.0 1.5 
25X dNTP mix (100mM) 0.8 0.15 
10X RT Random Primers 2.0 - 
5x miRNA primer  - 3.0 
MultiScribe Reverse 
Trascriptase  1.0 (1 U/µl) 1.0 (50 U/µl) 
Rnase Inhibitor (1 U/µl) 1.0 (1 U/µl) 0.19 (20 U/µl) 
Total RNA  13.2 (264ng) 5 (10ng) 
Nuclease-free water  - 4.16 
 
 
Table 8. The termal cycler’ program used to Reverse Transcription-PCR (RT-PCR) 
both for mRNA (A) and for miRNA (B) RT-PCR. 
  
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Table 9. Components used to prepare the PCR-Master Mix both for mRNA and for 
miRNA real time assay. 
 
Reagent Volume for 1 reaction 
(20µl) 
TaqManiversal PCR master mix 10.0 
Nuclease-free water     7.67 
20X TaqMan primer (labeled Real Time)  1.0 
cDNA    1.33 
 
 
 
Step Type Time (min) Temperature (°C) 
HOLD 1 10 25 
HOLD 2 120 37 
HOLD 3 5 85 
HOLD 4 ∞ 4 
Step Type Time (min) Temperature (°C) 
HOLD 1 30 16 
HOLD 2 30 42 
HOLD 3 5 85 
HOLD 4 ∞ 4 
 55 
reported in Table 9), and then loaded into the thermal cycler, using the following 
program: 1x (10’ at 95°C), 40x (15” at 95°C and 60” at 60°C).All reactions were run in 
triplicates on ABI Prism 7900HT Sequence Detection System 2.3 software, according 
to the 2-∆∆CT algorithm, to quantify the expression levels of miRNAs and mRNAs. The 
RQ levels were expressed as mean±standard error of the mean (SEM) between 3 
study groups (active CD and GFD patients vs control subjects). The levels of miR-
449a was normalized to RNU48 (Assay ID: 001006 Applied Biosystems), but the 
changes in NOTCH1 and HES1 mRNA expression levels were calculated following 
normalization to housekeeping gene β-actin (Assay ID: Hs99999903_m1 Applied 
Biosystems). The β-actin was chosen because several studies in literature used it as 
good housekeeping gene in the intestinal samples145-146. The normalization to 
endogenous controls was performed to correct for potential RNA input (variation in 
the amount of starting material, sample collection, RNA preparation and quality) or 
RT efficiency biases.  
 
Transfection and inhibition experiments  
Once miRNA targets were predicted with bioinformatic alghoritms, the next step was 
to validate the miRNA-target interaction experimentally. Infact, since computational 
methods are not perfect, and there is a risk of false-positive prediction, target 
validation in biological system is inevitable to complete the study of target prediction; 
usually the most common method to check the interaction between miRNA and its 
target mRNA directly is the “reporter assay”. In a standard reporter assay, the 
putative target sites are fused to a reporter construct (i.e. luciferase, green 
fluorescence protein or yellow fluorescence protein), and reporter expression is 
measured in the absence and presence of the miRNA. The plasmids used were 
pGL3-control encoding for firefly luciferase, a control luciferase reporter plasmid; they 
were co-transfected with pRL-NOTCH1, coding for Renilla luciferase under CMV 
promoter, including miR-449a binding site. The direction of the inserted 3’ UTR 
region was confirmed by PCR and sequencing after ligation. The cell lines used were 
human HEK-293 (human embryonic kidney cells) maintained in α-MEM (minimum 
essential medium) supplemented with 10% fetal bovine serum and glutamine. HEK-
293 cells were seeded in 24-well plates with 500 µl of antibiotic-free medium the day 
before transfection to allow adherence and to reach 70-90% confluence at the time of 
transfection. The standard co-transfection mix was prepared for triplicate samples by 
adding 10 ng pGL3-control, 500 ng pRL-NOTCH1 and pre-miR in 150 µl of Opti-MEM 
I (Invitrogen); 3 µl lipofectamine 2000 (Invitrogen) were added separately in 150 µl 
Opti-MEM I. The two solutions were mixed and incubated at room temperature for 
20’-30’, after which, 100 µl of the mix were added to each well. The final volume of 
medium plus transfection mix was 600 µl. Cells were incubated with the transfection 
mix for 6 h and the medium was then replaced with new fully supplemented culturing 
medium. Forty-eight hours after transfection, we measured firefly and Renilla 
luciferase activities using a dual luciferase assay according to the manufacturer’s 
instructions (Promega, Naples, Italy). 
 
Immunohistochemistry for NOTCH1, HES1, β-catenin and MUC-2. 
The NOTCH1, HES1, MUC-2 and β-catenin proteins were identified by 
immunohistochemical analysis on formalin-fixed paraffin-embedded small intestinal 
tissue blocks in CD patients and in controls. We selected randomly, six active CD, six 
GFD and four controls. Sections 5-µm thick were cut from the formalin-fixed tissue 
blocks, dewaxed in xylene analogs (Bio-Clear Bio-Optica, Milan, Italy) and re-
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hydrated with graded ethanol concentrations. The sections were incubated for 45 min 
at 97°C in retrieval solution pH 9 (DAKO, S2367) (NOTCH1) or in citrate buffer pH 6 
(DAKO, S2369) (HES1, MUC-2 and β-catenin) in order to retrieve immunogenicity. 
Endogenous peroxidase activity was blocked by immersing slides in 3% hydrogen 
peroxide methanol for 10’. Aspecific antigen sites were blocked by incubating at room 
temperature for 30’ with background reducing components (DAKO). The primary 
antibodies used in the immunohistochemical staining were anti cleaved NOTCH1 
rabbit monoclonal antibody (1:50 Cell Signaling Technology), anti-HES1 rabbit 
polyclonal antibody (1:1000 Abcam), anti mucin 2 (MUC-2) glycoprotein mouse 
monoclonal antibody (1:100 Leica Microsystems) and anti-β-catenin mouse 
monoclonal antibody (1:200 BD Transduction Laboratories). Tissue sections were 
incubated at room temperature for 1 h with primary antibodies. Staining was carried 
out with LSAB+System-HRP (DAKO); the signal was developed using 
diaminobenzidine (DAB) chromogen as substrate (DAKO). The tissue sections were 
then lightly counterstained with Mayer’s hematoxylin and cover-slipped. Because the 
MUC-2 staining of goblet cells was patchy, we picked ten crypts from each slide and 
manually counted the number of goblet cells stained in each crypt. We also 
evaluated MUC-2 staining of villi, when possible, in GFD patients and controls.  
 
Scanning and automated image analysis of NOTCH1, HES1 and β-catenin 
proteins 
We automated the quantification of the immunohistochemical signal because 
counting labeled cells was rather subjective. Thus, subjects sections of the small 
intestine were scanned with the NanoZoomer 2.0 system (Hamamatsu, Japan). The 
scanner was equipped with a 20x, 0.7 Numerical Aperture Plan-Apochromat lens. 
Digitization was performed with a lens (pixel size of 0.23 mm). The images were 
compressed into jpeg files by the NanoZoomer software. The files were transferred to 
the Definiens Analyst LS5.0 system (Definiens AG, Germany) that counted the 
NOTCH1, HES1 and β-catenin-positive and -negative cells and quantified the 
staining signal. The Definiens Analyst software (Definiens AG, Germany) is based on 
cognition network technology that is a semantic network of objects and their mutual 
relationships. Two rule sets, using cognition network language, were specifically 
written for this evaluation to automatically detect and measure the small intestinal 
area and to count positive and negative crypt cells. The signal was classified as 
intensely stained, low/moderate stained and unstained. Thus, both the percentage 
and intensity of labeled cells were taken into account. The detection and exclusion of 
areas not belonging to crypt was visually checked for all image files. The resulting 
data were transferred to an Excel sheet. Statistical differences in the 
immunohistochemical analysis between the study groups were evaluated using 
GraphPad Prism software. The Student “t” test was used for group comparisons and 
p<0.05 were considered statistically significant. 
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RESULTS 
 
Identification of miRNAs on small intestine through TLDA methodology 
In order to identify miRNAs differently expressed in small intestine that might be 
relevant in the development of celiac disease, 3 different groups of children were 
enrolled. The first group was composed of 17 patients with active CD; the second 
group was composed of 9 GFD celiac patients at gluten free-diet from at least 2 
years; the third group was composed of 11 control children negative for serum 
autoimmune markers and with normal intestinal architecture. For each patient a 
fasting serum sample was collected to test biochemical parameters and the presence 
of DQ2/DQ8 HLA susceptibility molecules. From all children enrolled in this study, a 
biopsy specimen from the distal duodenum was obtained; it was then divided in two 
aliquots: one was used for histopathological analysis and the other was liquid 
nitrogen frozen for the RNA extraction. The histopathological analysis of small 
intestine from all patients confirmed the CD diagnosis by showing the typical 
architectural abnormalities (intraepithelial lymphocytosis, or crypt hyperplasia and/or 
various degree of villous atrophy, according to Marsh IIIB or IIIC classification); 
whereas, in GFD patients and in controls, the mucosa was normal or showed a slight 
lymphocytosis (Marsh I classification). Total RNA was extracted from samples of 
small intestinal tissues from each subject. It was purified and quantified and only high 
quality RNA was used for the screening. The RNA was used to analyze miRNAs 
expression profile by TLDA. Generally, TLDA is a new methodology designed for 
analyzing gene expression patterns in many samples across a defined set of gene 
targets. TLDA consist of 384-well micro fluidic cards, pre-loaded with real-time PCR 
assays available for 365 human mature miRNAs; in literature, many groups used this 
card to study miRNAs profile in several tissues as brain147, blood148, breast cancer149 
and in acute leukemias91. To determine relative levels of miRNAs expression, the 
fluorescence data generated by TLDA for each card were elaborated with SDS 
software 2.3 using ∆∆Ct method. This method was used to calculate the changes in 
miRNA expression of all samples respect to a non-disease sample (calibrator). Assay 
normalization was performed versus the constitutively expressed RNU-48 
(endogenous control). MiRNAs whose mean RQ levels were ≤0.5 in almost CD 
patients [15/20 active CD (75%) and 7/9 GFD patients (78%)] were considered 
downregulated; miRNAs whose mean RQ levels were ≥2.0 in almost CD patients 
were considered upregulated. Expression profiling revealed that a large set of 
miRNAs were expressed in small intestine. Infact, Figure 11 showed the miRNA 
expression profile in the small intestine of children with active CD (panel A) and in 
children on a GFD (panel B). Ninety of the 365 (25%) miRNAs tested were not 
expressed in small intestine. Over 50% of miRNAs were expressed at similar levels 
in the two groups of CD patients and in control patients. On the contrary, the 
expression levels of about 20% of miRNAs (22% in active CD and 23% in GFD) were 
different between CD patients and controls. In detail, 33% (27 miRNAs) of these 
differently expressed miRNAs were upregulated (RQ≥2.0) in the active CD in 
comparison to controls and the 67% (55 miRNAs) remaining were downregulated 
(RQ≤0.5); they were listed in Table 10. Instead, in the GFD patients, 26% (22 
miRNAs) of these differently expressed miRNAs were up-regulated (RQ≥2.0) and 
74% (62 miRNAs) were down-regulated (RQ≤0.5) in comparison to controls; they 
were listed in Table 11. 
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Figure 11. MiRNA expression pattern in the small intestine of patients with 
active CD (A) and of CD patients on a GFD (B). Data are expressed as 
percentage of miRNAs tested (n=365). White areas, miRNAs whose 
expression levels were similar in the two CD groups and controls; gray 
areas, miRNAs not expressed;black areas, miRNAs whose expression 
levels differed between CD patients and controls [upregulated ↑(RQ≥2.0) or 
downregulated ↓(RQ≤0.5)].  
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Table 10. List of miRNAs differently expressed in  
active CD patients and controlsa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 In bold are miRNAs similarly expressed both in  
active CD and in GFD patients. 
Up regulated miRNAs Down regulated miRNAs 
miR-187 miR-133a 
miR-18a miR-135b 
miR-196b miR-139 
miR-213 miR-145 
miR-223 miR-185 
miR-337 miR-192 
miR-383 miR-194 
miR-424 miR-198 
miR-425 miR-199a 
miR-432 miR-204 
miR-554 miR-217 
miR-565 miR-224 
miR-575 miR-30a-3p 
miR-589 miR-30b 
miR-597 miR-30c 
miR-630 miR-30e-3p 
miR-639 miR-31 
miR-656 miR-34b 
miR-449a miR-369-3p 
miR-492 miR-422b 
miR-644 miR-485-3p 
miR-503 miR-509 
miR-196a miR-515-3p 
miR-504 miR-520h 
miR-500 miR-542-5p 
miR-330 miR-548d 
miR-182 miR-556 
 miR-579 
 miR-606 
 miR-608 
  miR-624 
  miR-651 
  miR-653 
  miR-96 
  
miR-105 
  
miR-124a 
  
miR-135a 
  
miR-189 
  
miR-202 
  
miR-219 
  
miR-299-5p 
  
miR-323 
  
miR-379 
  
miR-380-5p 
  
miR-409-5p 
  
miR-412 
  
miR-512-3p 
  
miR-566 
  
miR-576 
  
miR-600 
  
miR-614 
  
miR-616 
  
miR-618 
  
miR-631 
  
miR-659 
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Table 11. List of miRNAs differently expressed in GFD  
patients and controlsa 
 
Up regulated miRNAs Down regulated miRNAs 
miR-422a miR-99a 
miR-190 miR-100 
miR-422b miR-125b 
miR-489 miR-153 
miR-490 miR-203 
miR-518d miR-383 
miR-184 miR-432 
miR-193b miR-433 
miR-338 miR-518b 
miR-524 miR-622 
miR-627 miR-639 
miR-591 miR-132 
miR-205 miR-411 
miR-449a miR-376a 
miR-492 miR-410 
miR-644 miR-630 
miR-503 miR-99b 
miR-196a miR-105 
miR-504 miR-125a 
miR-500 miR-130a 
miR-330 miR-133b 
miR-182 miR-143 
 miR-148a 
 miR-17-3p 
 miR-193a 
 miR-27b 
 miR-589 
 miR-650 
 miR-422a 
 miR-190 
 miR-422b 
 miR-489 
 miR-490 
 miR-518d 
 miR-184 
 miR-193b 
 miR-338 
 miR-524 
 miR-627 
 miR-591 
 miR-205 
 
miR-105 
 
miR-124a 
 
miR-135a 
 
miR-189 
 
miR-202 
 
miR-219 
 
miR-299-5p 
 
miR-323 
 
miR-379 
 
miR-380-5p 
 
miR-409-5p 
 
miR-412 
 
miR-512-3p 
 
miR-566 
 
miR-576 
 
miR-600 
 
miR-614 
 
miR-616 
 
miR-618 
 
miR-631 
 
miR-659 
 
a
 In bold are miRNAs similarly expressed both in active CD  
and in GFD patients. 
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The comparison bethween these two tables, evidentiated 30 miRNAs with similar 
expression levels in both CD patients vs controls; particularly, 9 were upregulated 
and 21 were downregulated (Table 12). It’s interesting to notice that miR-124a, miR-
189, miR-299-5p and miR-379, downregulated in CD patients, were described in 
literature in association with autoimmune disorders. Particularly, miR-124a levels 
were significantly decreased in rheumatoid arthritis150; miR-189 and miR-379 levels 
were decreased in idiopathic thrombocytopenic purpura151; miR-299-5p levels “were 
increased” in primary biliary cirrhosis152. Among the miRNAs upregulated both in 
active CD and in GFD patients, miR-449a was expressed at very high levels: in all 
active CD the mean RQ±SEM was 55.18±16.45; in GFD children the mean RQ±SEM 
was 15.43±7.69.  
 
qRT- PCR for miR-449a 
The successive step was to perform a qRT-PCR in order to confirm the high level of 
miR-449a. Real-Time PCR assay is a highly sensitive approach for identifying 
miRNA profiles153. For this assay, we used stem-loop RT primers rather than 
conventional linear ones, because of their higher specificity and sensitivity likely due 
to the base stacking and spatial constraint of the stem-loop structure. The assays 
target only mature miRNAs, not their precursors, ensuring biologically relevant 
results. In almost all patients, miRNA profiling data correlated with qRT-PCR data; in 
fact, the expression levels of miR-449a were confirmed in active CD patients with a 
mean RQ±SEM of 2.8±0.9. 
 
Identification of miRNA targets  
Next, a bioinformatic approach was performed to select target genes of the miR449a.  
A gene target of miRNA regulation, might be predicted by various computational 
algorithms which utilize distinct parameters (such as base pairing pattern, 
thermodynamic stability of miRNA-mRNA hybrid, comparative sequence analysis to 
check conservation and examination of the presence of multiple site) to predict the 
probability of a functional miRNA binding site within a given mRNA target. Infact, 
computational algorithms have been the major driving force in predicting miRNA 
targets154. We used the bioinformatic algorithm Mirecords. Mirecords, for miR-449a, 
gave a list of 32936 predicted gene targets. So, to further reduce the number of 
putative repressed gene targets by miR-449a, they were selected if predicted by two 
or more programs and on basis of the best score allocated by different algorithms. In 
detail, six of the 11 programs of mirecords [Target Scan 5.1, PicTar, Miranda 1.9, 
MirTarget2 (v2.0), PITA (Catalog version 3) and RNAhybrid (V2.2)] identified several 
proteins that are present in relevant biological pathways.  
 
Identification of interesting pathways 
The list of these good gene targets was then combined and analyzed using 
WebGestalt to detect probably pathways in which they were involved. Particularly, 
GOTM and KEGG database were used to identify the biological pathways predicted 
to be deregulated by miR-449a; they were then sorted in functional groups and were 
reported in Figure 12. The functional groups selected were: 
 cell organization and function 
 cell cycle and cancer 
 macromolecules biosynthesis 
 metabolism 
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Table 12. List of miRNAs (n=30) differently expressed in CD patients 
and controls but with similar expression levels both in active CD and  
GFD children. Data are reported as RQa levels (mean ± SEM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aRQ=2-∆∆CT represents miRNA fold change in CD patients vs mean  
value obtained in control patients. 
 
miRNA 
 
 
Active CD 
 
 
GFD 
 
miR-449a 55.18 ± 16.45 15.43 ± 7.69 
miR-492 48.88 ± 14.56 26.86 ± 9.00 
miR-644 47.80 ± 8.80 37.53 ± 18.85 
miR-503 19.84 ± 2.36 20.55 ± 8.07 
miR-196a 11.06 ± 2.84 8.45 ± 1.01 
miR-504 5.54 ± 0.83 8.02 ± 2.86 
miR-500 5.49 ± 0.70 7.88 ± 1.56 
miR-330 3.84 ± 0.45 2.48 ± 0.11 
miR-182 2.95 ± 0.42 2.75 ± 0.13 
miR-105 0.37 ± 0.03 0.25 ± 0.03 
miR-124a 0.20 ± 0.02 0.21 ± 0.05 
miR-135a 0.21 ± 0.05 0.38 ± 0.05 
miR-189 0.15 ± 0.05 0.21 ± 0.06 
miR-202 0.12 ± 0.06 0.17 ± 0.08 
miR-219 0.10 ± 0.01 0.27 ± 0.08 
miR-299-5p 0.11 ± 0.006 0.15 ± 0.05 
miR-323 0.11 ± 0.01 0.23 ± 0.08 
miR-379 0.30 ± 0.05 0.23 ± 0.1 
miR-380-5p 0.25 ± 0.03 0.28 ± 0.04 
miR-409-5p 0.35 ± 0.04 0.31 ± 0.05 
miR-412 0.13  ± 0.03 0.18 ± 0.01 
miR-512-3p 0.27 ± 0.03 0.26 ± 0.04 
miR-566 0.29 ± 0.02 0.23 ± 0.03 
miR-576 0.15 ± 0.04 0.4 ± 0.1 
miR-600 0.19 ± 0.02 0.22 ± 0.06 
miR-614 0.26 ± 0.02 0.21 ± 0.02 
miR-616 0.17 ± 0.04 0.11 ± 0.03 
miR-618 0.18 ± 0.03 0.32 ± 0.07 
miR-631 0.34 ± 0.03 0.27 ± 0.04 
miR-659 0.33 ± 0.03 0.30 ± 0.05 
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Figure 12. Functional pathways predicted for miR-449a. Genes with most favorable 
context score, obtained using TargetScan 5.1 program, were sorted into pathways 
using GOTM and then combined into functional groups. The number of genes for 
each functional group was reported.  
*: presence of NOTCH1 gene in the functional group 
.
81 * 
10 * 
53 * 
218 * 
Cell organization and function 
Cell cycle and cancer 
Macromolecule biosynthesis 
Metabolism 
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It was interesting to notice that several genes were redundant in these groups and 
belonging to Notch pathway; they were:  
 NOTCH1 (neurogenic locus notch homolog protein 1) 
 KLF-4 (Krueppel-like factor-4) 
 DLL (delta-like 1) 
 LEF1 (lymphoid enhancer-binding factor 1) 
 NUMBL (numb homolog-like) 
 
Luciferase assay and validation of the interaction between miR-449a and 
NOTCH1 3’UTR 
The interaction between miR-449a and the 3′ UTR of NOTCH1 was validated using 
the luciferase reporter assay. The luciferase reporter assays is common experimental 
reporter system able to verify predicted miRNA/mRNA pairings on the basis that the 
binding of a given miRNA to its specific mRNA target site will repress reporter protein 
production thereby reducing activity/expression that could be measured and 
compared to a control. In cells co-transfected with pRL-NOTCH1 vector and pre-miR-
449a, a pre-miR-449a concentration of 100 nmol/L was sufficient to significantly 
reduce (p=0.001) Renilla luciferase activity vs control values after 48h (Figure 13). 
This finding confirmed that there is an effective, specific and functional interaction 
between miR-449a and the 3’ UTR of NOTCH1. It suggests that changes in miR-
449a levels may effectively modulate the expression of NOTCH1. 
 
qRT- PCR for NOTCH1 and HES1  
To confirm the expression of NOTCH1 and HES1 mRNA in small intestine of CD 
patients vs controls, we performed the qRT-PCR; the data were normalized vs the 
house-keeping gene β-actin. In CD patients vs controls, the levels of NOTCH1 and 
HES1 mRNAs (expressed as RQ±SEM) were 3.4±1.3 and 2.2±0.6 respectively; in 
GFD patients were RQ±SEM: 6.5±4.7 and 4.2±2.9, respectively. These data confirm 
that NOTCH1 and HES1 are expressed in small intestine and their levels are up-
regulated in CD patients respect to controls. 
 
Immunohistochemistry for NOTCH1 and HES1  
We next investigated the protein expression of NOTCH1 and of HES1, in small 
intestinal biopsies from CD patients and controls. Figure 14 shows an example of the 
results obtained for NOTCH1. NOTCH1 was more homogeneously distributed and 
expressed at a higher level in the intestinal crypts of controls than in crypts of CD 
patients (panel A, left). On the right are the images converted for automated analysis 
(white: unstained cells, yellow/orange: low/moderately stained cells, brown: intensely 
stained cells). Significantly more intensely stained and less unstained cells (p=0.02) 
were detected in controls than in the two groups of CD patients (Figure 14, panel B). 
These results indicate that NOTCH1 is less expressed in the small intestine of CD 
patients than in controls. 
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Figure 13. Validation of miR-449a and 3’-UTR NOTCH1 mRNA interaction.  
miR-449a binds and functionally interacts with NOTCH1 3′ UTR. Pre-miR-449a 
inhibited the expression of a Renilla luciferase-expressing construct that contains 
the 3′ UTR region of the NOTCH1 gene harboring miR-449a putative binding sites 
after 48 h. 
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Figure 14. Immunohistochemistry of NOTCH1 in small intestine. A. Left, an example 
of NOTCH1 staining; Right, images converted for automated analysis (white: 
unstained cells, yellow/orange: low/moderately stained cells, brown: intensely stained 
cells). (Original magnification 40X). B. Evaluation of NOTCH1 stained/unstained cells 
in CD patients (6 active CD and 6 GFD patients) and in controls (n=4). Data are 
expressed as mean percent of intensely stained, low-moderately stained and 
unstained cells of the total intraepithelial cells (IECs). 
A B 
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Because in CD patients, the NOTCH1 mRNA levels were high and the protein levels 
were down, it may suggest a regulation post-trascriptional of this receptor. Figure 15 
shows an example of the results obtained for HES1. HES1 was more 
homogeneously distributed and expressed at a higher level in the intestinal crypts of 
controls than in those of active CD and GFD patients (panel A). On the right are the 
images converted for automated analysis. Significantly more intensely stained cells 
were detected in controls than in CD patients (p=0.02) and significantly less 
unstained cells were detected in controls than in active CD patients (p=0.03) (Figure 
15B). These results indicate that HES1 is less expressed in the small intestine of CD 
patients respect to controls. Because HES1 is a well know target gene of NOTCH1, it 
is possible that NOTCH1 signaling is altered in patients affected by CD. 
 
Immunohistochemistry for β-catenin and MUC-2 
Because NOTCH1 signals interact with the Wnt pathway to influence the intestinal 
stem cell fate, we investigated both the Wnt pathway (using β-catenin antibodies) 
and secretory goblet cells (using anti- MUC-2 antibodies). The Figure 16 shows a 
similar β-catenin expression in CD and control children, suggesting that this pathway 
not is altered in CD. Further, the Figure 17A and B show a statistically fewer MUC-2-
stained cells in the crypts of CD patients; infact in active CD patients the goblet cells 
number was 18±1.6, in GFD patients was 15±3 and in controls was 35.0±7.7(mean 
number of cells± SD) (p=0.04). In confirmation of this data, the number of goblet cells 
in the villi of GFD patients and controls was 7.0±1.8 and 20.0±4.9 respectively 
(p=0.04). 
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Figure 15. Immunohistochemistry of HES1 in small intestine. A. Left, an example of 
HES1 staining. Right, images converted for automated analysis (white: unstained 
cells, yellow/orange: low/moderately stained cells, brown: intensely stained cells). 
(Original magnification 40X). B. HES1 stained/unstained cells evaluated in CD 
patients (6 active CD and 6 GFD patients) and in controls (n=4). Data are 
expressed as mean percent of intensely stained, low-moderately stained and 
unstained cells of the total intraepithelial cells (IECs).  
 
A B 
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Figure 16. Immunostainings with β-catenin in small intestinal crypts from active 
CD, GFD and controls (Original magnification 40X). 
A B ACTIVE CD 
GFD 
CTRL 
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Figure 17. Immunohistochemistry of goblet cells in small intestine. A. An 
example of staining for MUC-2 shows fewer MUC-2 stained cells in active CD 
and in GFD patients than in controls (CTRL). (Original magnification 20X). B. 
MUC2 stained cells evaluated in CD patients (6 active CD and 6 GFD patients) 
and in controls (n=4). Data are expressed as mean of the number of goblet 
cells/crypt measured in 10 crypts/children.  
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DISCUSSION 
 
During the last decades, several evidences suggested that microRNAs regulate basic 
cellular functions including proliferation, differentiation and death155; dysregulation of 
miRNA expression has been extensively described in a variety of diseases, including 
cancer, obesity, diabetes and schizophrenia; therefore, it is important to identify and 
validate miRNA/mRNA target pairs. This study identified for the first time, both 
miRNAs expression pattern in human small intestine and miRNAs differently 
expressed in the jejunal biopsies of CD children vs control by TLDA. Some miRNAs, 
such as miR-124a, miR-189, miR-299-5p and miR-379, precedently described in 
association with autoimmune disorders156, are downregulated in both active CD and 
GFD patients, suggesting that they are involved also in celiac disease, whether the 
disease is active or not. About 20% of miRNAs differs bethween patients and 
controls. A global analysis of these miRNAs, identified miR-449a as microRNA 
probably involved in CD pathogenesis. Infact, miR-449a has the highest level among 
miRNAs upregulated in active CD patients. The most obvious function of miR-449a, 
in analogy with miR-34, is induction of apoptosis; infact, the levels of miR-449a are 
reported to be lower in various tumor-derived cell lines (lung adenocarcinoma, 
osteosarcoma, testicular cancer, colorectal cancer) than in the respective normal 
human tissues, which suggests that miR-449a exerts tumor suppressor activity93,157.  
The bioinformatic analysis showed that, among several targets predicted for miR-
449a, there were most redundant and with favourite score, genes belonging to the 
Notch pathway: NOTCH1, KLF-4, DLL1, LEF1 and NUMBL. Using a qRT-PCR, we 
confirmed that NOTCH1 and HES1 mRNA are expressed in small intestine of both 
CD patients and controls; in addition, we observed that these mRNAs are higher 
expressed in celiac small intestine than in the controls. After verifying the interaction 
between miR-449a, we evaluated the NOTCH1 protein in small intestinal biopsies of 
CD children. NOTCH1-positive cells were significantly fewer in biopsies from CD 
patients vs controls. Similar results were obtained with HES1, a target gene of 
NOTCH1158. In fact, HES1-stained cells were fewer in CD patients than in controls. 
Globally, these data indicate that the Notch pathway is dysregulated in CD children, 
irrespective of whether the disease is active or not, and that this alteration correlates 
with the very high miR-449a expression levels. Because NOTCH1 protein was less 
present in CD than in controls, but mRNA levels were similar, we speculated that this 
receptor could be regulated at post-trascriptional level. Data in literature showed that 
the Notch deactivation in intestine, leads to a complete loss of proliferating transient 
amplifying cells followed by their conversion into postmitotic goblet cells113; 
conversely its costitutive expression in the gut inhibited differentiation of crypt 
progenitor cells resulting in an intestine that largely consists of undifferentiated 
transient amplifying cells128. These complementary loss- and gain-of-function studies 
suggest that Notch signaling is a gatekeeper of the progenitor/stem cell compartment 
of the gut97. This study shows that in celiac small intestine, in association with high 
levels of miR-449a and with an altered NOTCH1 signals, the number of goblet cells 
were lower compared with controls. Ciacci et collegues, in according with these data, 
reported fewer goblet cells/mm2  in untreated (29.1) and in treated CD patients (42.2) 
than in controls (50.5), although the differences were statistically significant only in 
untreated patients (p<0.02)159. Conversely, in a mouse model, activation of NOTCH1 
resulted in a reduction of goblet cells128. The differences between mouse and human 
models and the more complex effect exerted by miRNAs on many gene targets, 
respect to knock out a single gene, could explain these apparently contrasting 
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results. In literature it is shown that the Notch pathway plays a central role in 
intestinal homeostasis in cooperation with other pathways, such as Wnt signals128; 
moreover, experimental data obtained in double transgenic mice indicated that the 
effect of Notch activation on goblet cell differentiation is independent of Wnt 
signals128. The Wnt pathway in the small intestine of our CD patients, evaluated 
through β-catenin, did not differ from that of control children. This result is in 
agreement with the western blot data obtained by Ciccocioppo160 and by Juuti-
Uusitalo161. However, the nuclear localization of β-catenin that is more evident in the 
small intestinal crypts from our active CD and GFD patients than in controls is a sign 
of activation of the Wnt pathway, in agreement with a previous report. In addition, it is 
interesting to note that besides NOTCH1, KLF-4 is also a target gene of miR-449a. 
KLF-4 has been reported to be a master regulator of goblet cell differentiation in the 
colon126. In fact, in KFL-4-/- mice, goblet cells were depleted by 90% in the colon, and 
the expression of MUC-2 was patchy throughout the colonic epithelium, indicating 
that KLF-4 is required for correct goblet cell maturation162. Given KLF-4’s regulation 
of goblet cell differentiation in the colon126, it is possible speculate that also in small 
intestine KLF-4 inhibition, by upregulated miR-449a, could thereby contribute to the 
depletion of goblet cells observed in our CD patients. Obviously, further experiments 
are necessary to verify this hypothesis. In conclusion, the maintenance of a correct 
number of functional goblet cells is required for the homeostasis of the intestinal 
mucosal environment, and deficiencies in the mucin composition renders the mucosa 
more susceptible to damaging agents in the lumen162-164. In fact, loss of goblet cell 
function leads to spontaneous colitis in mice165 and an altered mucous layer, 
increased rod-shaped bacteria and INF-γ mRNA levels were found in intestine from 
CD patients166. These findings globally, indicate that the small intestinal epithelium of 
CD patients is different from that of controls subjects. Infact, as it is well known, the 
active celiac disease is characterized by an inversion of the 
differentiation/proliferation program of the intestine with a reduction in the 
differentiated compartment, up to complete villi atrophy, and an increase of 
proliferative compartment, with crypt hyperplasia167,161. Furthermore, although GFD 
intestinal mucosa is characterized by an apparently normal mucosal architecture, it 
can also be associated with increased crypt cell proliferation (Barone M.V. et al., 
personal communication). Interestingly, in our study the number of goblet cells was 
significantly lower in the two CD groups than in control children. Based on these 
experimental data, we suggest that the altered mucus layer observed in our CD 
children could derange the protective function of the mucosal barrier that interfaces 
with the environment, thereby resulting in the altered permeability that has been 
reported in treated and untreated CD patients164,168. This alteration is not related to 
inflammation; in fact, it occurred in both the active CD and GFD patients. In 
conclusion, we investigated miRNA expression in celiac small intestine and detected 
very high miR-449a expression levels in both active CD and GFD patients.  
This finding could represent an epigenetic mechanism of gene regulation that is 
associated with a reduced NOTCH1 pathway and with decrease of differentiation of 
intestinal cells towards the secretory goblet cell lineage.  
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Abstract
Background: Maturity onset diabetes of the young type 2 (or GCK MODY) is a genetic form of diabetes mellitus provoked by
mutations in the glucokinase gene (GCK).
Methodology/Principal Findings: We screened the GCK gene by direct sequencing in 30 patients from South Italy with
suspected MODY. The mutation-induced structural alterations in the protein were analyzed by molecular modeling. The
patients’ biochemical, clinical and anamnestic data were obtained. Mutations were detected in 16/30 patients (53%); 9 of
the 12 mutations identified were novel (p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp, p.Gly162Asp, p.Thr168Ala,
p.Arg392Ser, p.Glu290X, p.Gln106_Met107delinsLeu) and are in regions involved in structural rearrangements required for
catalysis. The prevalence of mutation sites was higher in the small domain (7/12: ,59%) than in the large (4/12: 33%)
domain or in the connection (1/12: 8%) region of the protein. Mild diabetic phenotypes were detected in almost all patients
[mean (SD) OGTT= 7.8 mMol/L (1.8)] and mean triglyceride levels were lower in mutated than in unmutated GCK patients
(p = 0.04).
Conclusions: The prevalence of GCK MODY is high in southern Italy, and the GCK small domain is a hot spot for MODY
mutations. Both the severity of the GCK mutation and the genetic background seem to play a relevant role in the GCK
MODY phenotype. Indeed, a partial genotype-phenotype correlation was identified in related patients (3 pairs of siblings)
but not in two unrelated children bearing the same mutation. Thus, the molecular approach allows the physician to confirm
the diagnosis and to predict severity of the mutation.
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Introduction
Maturity onset diabetes of the young (MODY; MIM #606391)
is a genetically and clinically heterogeneous form of diabetes
mellitus, characterized by an early age at onset, a primary defect in
beta-cell function and an autosomal dominant inheritance [1].
Among the different types of MODY diabetes described thus far,
each of which is due to a different gene mutation (HNF4A, GCK,
HNF1A, IPF1, HNF1B, NEUROD1, CEL) [2,3] the GCK
MODY form is provoked by mutations in the glucokinase gene
(GCK; MIM#138079).
The glucokinase gene on chromosome 7p15.3-p15.1 consists of
12 exons that span ,45.169 bp and encode a 465-amino-acid
protein [4], and three tissue-specific isoforms are known [5]. Thus
far, about 200 GCK mutations have been reported and its
frequency is higher in European Caucasians, particularly in those
from France and Italy [6]. The identification of a GCK mutation
in subjects whose clinical phenotype is suggestive of MODY
usually distinguishes patients with a benign prognosis (GCK
MODY) from those with a severe hyperglycemia (HNF1A MODY
and other MODY forms) because the diagnosis cannot be always
made on clinical grounds alone.
Glucokinase (also called hexokinase IV) catalyzes the ATP-
dependent phosphorylation of glucose to glucose-6-phosphate. It is
homologous to hexokinases I, II and III, but its lower affinity for
glucose, restricted localization to a few cell types and peculiar
kinetic properties, compared to those of the other hexokinases,
confer it distinctive properties. Indeed, GCK acts as a glucose
sensor in the pancreas and liver, and presents a peculiar sigmoidal
glucose saturation curve, which indicates cooperative behaviour.
Elucidation of crystal structure of GCK yielded data that could
help to establish structure-function correlations [7]. Indeed, the
protein folds into two domains known as the small and the large
domain with the glucose binding site in between. An unexpected
‘‘super-open’’ form and a ‘‘closed’’ form of the enzyme were
identified [7]; the latter is similar to the form found in the
hexokinase I structure [8]. The two forms differ in the relative
spatial orientation of the two domains. The catalytic mechanism
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requires dramatic GCK conformational changes. In fact, when
bound to glucose, the enzyme goes from the super-open inactive
form to the closed form. Therefore, the inter-domain motions are
crucial for the enzyme activity.
In this study, we report the identification of 9 novel and 3
known mutations of the GCK gene in children from south Italy. All
mutations co-segregated with the diabetic phenotype in the
respective families and resulted in perturbation of the 3D structure
of the protein. Our data show that molecular screening is useful in
the diagnosis of MODY because it allows to confirm the diagnosis
and to predict severity of the mutation.
Methods
Subjects
Thirty patients aged 1–14 years, 9 boys and 21 girls whose
clinical presentation was suggestive of MODY were selected for
GCK gene screening from among 240 diabetic children seen in the
Paediatric Clinic of our Medical School between 2001 and 2006.
Other MODY genes were not investigated. Most patients were
unrelated; 6 were except (3 pairs of siblings, 1: M022–M023, 2:
M024–M025, 3: M028–M029). Inclusion criteria were: early onset
(,25 years) of diabetes, mild hyperglycemia, no autoimmune
markers of type I diabetes, without obesity [c.o. body mass index
(BMI) z score .2] and family history of diabetes for at least two
consecutive generations [1,9]. No treatment was administered to
the patients and no diabetes complications were evident up to
diagnosis. A fasting blood sample was drawn from both parents of
mutated patients and from 100 unrelated controls, who came from
the same geographical area, and used for the GCK molecular
characterization. The parents of all subjects gave their written
informed consent to the study. The research was conducted
according to Helsinki II declaration and approved by the ethics
committee of our Faculty.
Clinical and anamnestic examination
We collected the following data for each patient upon
diagnosis: age, birth weight, family history of diabetes and/or
other diseases and BMI. The BMI was transformed into BMI-z-
score (z-BMI) based on the Centre for Disease Control normative
curves [10,11].
Biochemical analyses
The following biochemical parameters were measured on
fasting blood samples: plasma glucose (FPG) by the enzymatic
hexokinase method and triglycerides by the standard enzymatic
method (Hitachi Modular, Tokyo, Japan); glycosylated haemo-
globin (HbA1c) by HPLC (HLC-723 G7 TOSOH Bioscience
Tokyo, Japan); serum insulin by the chemiluminescence method
(Immulight 2000; Medical System Genoa, Italy). After an oral
glucose dose of 0.75g/kg body weight (maximum 75 g), oral
glucose tolerance test (OGTT) was evaluated on blood samples
collected every 30 min up to 2 h. The first-phase insulin response
(FPIR) was calculated as the sum of T+1 and +3 min serum insulin
concentrations, evaluated after an i.v. glucose dose of 0.5 g/kg
body weight in 3 min [12].
DNA extraction
Genomic DNA from patients, parents and controls was
extracted from a blood sample plus EDTA using Nucleon BACC
2 kit (Amersham Biosciences Europe, Milan, Italy).
Sequence analysis
Exons and flanking intron regions of GCK, including tissue
specific variants of exon 1, were amplified by PCR using
previously reported primers (exons 1a, 2, 3, 4) [13] or chosen by
the Primer 3 program (exons 1b, 1c, 5, 6, 7, 8, 9 and 10) [14]. The
PCR mixture contained in a final volume of 50 ml: 20 mM each
primer, 1x PCR buffer (Applied Biosystems, Foster City, CA,
USA), 10 mM each deoxynucleotide triphosphate, 2.5 U of Taq
DNA polymerase (Applied Biosystems) and 200 ng of genomic
DNA. Each PCR was performed on Gene-Amp PCR system 9700
thermocycler (Applied Biosystems) and consisted of a initial
denaturation step at 95uC for 5 min and a final extension at
72uC for 7min.
The primers and PCR conditions are detailed in table 1.
Product sizes were evaluated by agarose gel electrophoresis and
amplicons were sequenced in both directions using the Big Dye
terminator sequencing kit (Applied Biosystems) on ABI PRISM
sequencing apparatus 3730 (Applied Biosystems). We preliminarily
analyzed the GCK coding sequence of a healthy subject by
sequence analysis and verified that it overlapped the wild-type
reference sequence (GenBank NM_000162). All sequences of the
Table 1. Primers used for PCR amplification of GCK exons and PCR conditions.
Exons1 Forward primer Reverse primer
PCR annealing
temperatures
PCR annealing
times
PCR extension
times (72uC)
Number of
cycles
1a (2) 59-TCCACTTCAGAAGCCTACTG 59-TCAGATTCTGAGGCTCAAAC 60uC 30’’ 60’’ 35
1b 59-AGCAGGCAGGAGCATCTCTG 59-GCTGCTCTCCCAGTGCAAAG 62uC 20’’ 60’’ 30
1c 59-GGCCAACTGCTACTTGGAAC 59-AGGAGGTGAGAAGCCTGGAG 54uC 20’’ 30’’ 35
2 (2) 59-TGCAGATGCCTGGTGACAGC 59-CACAGCTGCTTCTGGATGAG 60uC 15’’ 30’’ 30
3 (2) 59-TAATATCCGGCTCAGTCACC 59-CTGAGATCCTGCATGCCTTG 57uC 15’’ 30’’ 30
4 (2) 59-TAGCTTGGCTTGAGGCCGTG 59-TGAAGGCAGAGTTCCTCTGG 62uC 20’’ 60’’ 30
5/6 59-TCTGAGCCTGTTTCCTCAGC 59-GGCCCTTGAAGCCTGTTGTA 57uC 20’’ 45’’ 35
7 59-CCAGACAAAGCAGAGACAGG 59-TGCTTTTCCCCAGAGTTGTT 54uC 20’’ 45’’ 35
8 59-TGGCTCATTAACGAGGGAAA 59-CTGAGACCAAGTCTGCAGTG 51uC 15’’ 45’’ 35
9 59-CCCTCCCTGGAGAACGAGAG 59-AATCTTGGAGCTTGGGAACC 60uC 20’’ 45’’ 35
10 59-GAGTCTTCTCGACCCCCTTG 59-CACCGAAAAACTGAGGGAAG 55uC 20’’ 45’’ 35
1GenBank: accession nu (AH005826)
2Taken from Stoffel M. et al. 1992 Proc Natl Acad Sci USA 89:7698–7702.
doi:10.1371/journal.pone.0001870.t001
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patients were analyzed and compared with the wild-type published
reference sequence with the ABI Seqscape software v2.5 (Applied
Biosystems).
All mutations were also validated on a second PCR product.
Finally, the children’s parents and 100 unrelated healthy
individuals were screened for these mutations.
Conservation of residues was evaluated from a multiple
sequence alignment of 15 sequences in the PFAM349 and
PFAM3724 protein families [15]. The result was validated by a
multiple sequence alignment of 341 protein sequences homolog to
GCK and extracted from the non redundant sequence database
RefSeq, available online [16]. Furthermore, for the 1v4s structure,
a multiple sequence alignment of 143 sequences in the
ConSurf_HSSP database [17] was carried out. The outcomes
from the three approaches were in accordance.
Statistical analysis
Continuous variables are reported as mean (SD) and compar-
isons among variables were made with the t- test. Inter-group
differences were considered statistically significant at p,0.05.
We calculated the distribution in the large domain, in the small
domain and in the connection region of the protein of our GCK
mutations and of those described in literature.
Mutations nomenclature
All mutations are described according to the recommended
nomenclature available online [18–20]. Nucleotide numbers are
derived from cDNA GCK sequence (GenBank NM_000162)
considering nucleotide +1 the A of the first ATG translation
initiation codon in the reference sequence.
Molecular modelling
We used molecular modelling to investigate alterations of the
GCK 3D structure and dynamics associated to the various
mutations. The active form of GCK served as template because it
has the highest resolution structure (2.3 A˚, PDB code: 1v4s) [7].
Under the assumption that point mutations are likely to preserve
the overall fold of the proteins, it follows the procedure for
generating models. The first step of this procedure is the prompt
substitution of the residues, which we did with the program
MODELLER [21]. The program replaces the side chains by
selecting the most abundant conformers and performs a simulated
annealing procedure to optimize side chain conformations. This
was followed by energy minimization in explicit solvent with the
GROMACS program [22] using the GROMOS96 force field
[23]. Finally, the system was optimized by means of a short
molecular dynamics calculation of 1ns. The calculation was made
by restraining the main chain conformations and allowing the side
chain dynamics. The notation used for secondary structure was
taken from Kamata et al. [7]. Accordingly, sequences 1–64 and
206–439 belong to the large domain, sequences 72–201 and 445–
465 belong to the small domain, and sequences 65–71, 202–205
and 440–444 belong to the three loops connecting the domains.
Results
Table 2 shows the molecular characterization of the 16/30 our
diabetic children who had mutations in the GCK gene. Ten
patients were unrelated (two of these had the same mutation) and 6
were siblings from 3 families. Therefore, GCK MODY diagnosis
was confirmed in these 16 patients. All mutations were detected at
the heterozygous state, 9 mutations were novel; 8 of them caused
variations in amino acid residues well conserved among species,
and one produced a truncated protein of 289 amino acids
(p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp,
p.Gly162Asp, p.Thr168Ala, p.Arg392Ser, p.Glu290X,
p.Gln106_Met107delinsLeu). Three other GCK mutations were
already known; 2 of them caused truncated proteins (p.Lys39fsX6
and p.Ser453X) [24,25] and 1 was a missense mutation
(p.Glu265Lys) (Bellane´-Chantelot C et al. Abstract, Diabetologia
1998; 41:A109, 423). The structural analysis of mutation sites
indicated 3D clustering. In fact, among the GCK variants in our
population, 7/12 (,59%), 4/12 (33%) and 1/12 (8%) were
localized in the small domain, in the large domain and in the
connecting loops, respectively (Fig. 1). The effects of GCK
mutations on the enzyme’s 3D structure are reported in Table 2.
Figures 2 and 3 show the structural features of some of the new
mutations detected in our GCK MODY patients.
Table 3 shows the phenotypic characteristics of our mutated
children at diagnosis. All mutations were also present in either the
mother or the father of the GCK MODY patients in association
with diabetes and mean birth weight did not differ between
children who inherited GCK mutations from their father or
mother (2.84 kg vs 2.98 kg). Almost but one patient had mild
hyperglycemia [mean (range) FPG = 6.60 (5.7–7.9) mmol/L,
M013 = 10.0 mmol /L], mildly altered OGTT [mean (SD) 2 h
OGTT = 7.8 (1.8) mmol/L] and 2h increment always ,2.8 except
in two patients: M024 = 3.3 and M005 = 4.9; FPIR values between
24.6 and 156.0 mU/mL and slightly elevated levels of HbA1c
[mean (SD) HbA1c = 6.1 (0.4) %]. The mean triglyceride
concentration (0.58 mmol/L) was lower in our mutated patients
(p = 0.04) than in unmutated GCK MODY patients (0.80 mmol/
L) and below 50th percentile of our laboratory age-related
reference range (0.36–1.10 mmol/L).
Discussion
In our Italian population, GCK gene mutations account for 6%
(16/240) diabetic children and for 53% (16/30) with suspected
MODY. This GCK MODY prevalence is in line with those
detected in southern European countries, particularly in France
and in Italy, namely between 8% and 56% [25–27]. An analysis of
the 3D structure of the protein mutants yielded evidence of
structural perturbations, which supports the GCK MODY-
causing nature of these mutations. In particular, the p.Glu70Asp
mutation (detected in 1 patient) substitutes the highly conserved
glutamate with aspartate. These amino acids are polar acidic
residues but the binding to lysine 458, in the a13 helix, appears to
be weakened compared with the wild-type enzyme. This
substitution could slightly modify enzymatic activity and/or
stability. Substitution of glutamate by lysine is reported, in
association with diabetes, to reduce the enzyme’s glucose affinity
but protein stability is preserved [28].
The p.Gln106_Met107delinsLeu mutation (detected in 1
patient) altered respectively, a poorly and moderately conserved
amino acid. It produces a protein in which residues Gln106 and
Met107 are substituted by a leucine. This mutation occurs on an
edge strand of the b-sheet of the small domain. The b-sheet
encompasses the a13 helix in the closed form. Because the
conformational features of this region are essential for super-open/
closed conversion, the deletion could influence GCK function. A
gene deletion encompassing GCK exon 2 (p.Val16_Glu70del) has
recently been described in a UK diabetic patient by multiplex
ligation-dependent probe amplification assay and it co-segregated
with early onset diabetes within the pedigree [29]. The
p.Phe123Leu mutation (detected in 1 patient) altered a highly
conserved amino acid. Phe 123 is located on the a3 helix within
the small domain. Phe 123 is projected into the hydrophobic core
Glucokinase Gene Mutations
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of the domain thereby contributing to its stability. The substitution
of a phenylalanine with a leucine is not dramatic in terms of
hydrophobicity, however, it introduces a cavity in the hydrophobic
core. This may affect inner surface complementarity thereby
influencing the structural stability and the dynamical behaviour of
the domain with consequences at a functional level.
In mutant p.Asp132Asn (detected in 2 related patients), the
acidic negatively charged aspartate, located in the a3 helix that
belongs to the small domain, is changed into the uncharged
asparagine. Aspartate 132 is a poorly conserved amino acid and
this variant probably provokes only mild structural alterations. In
fact, the 2 siblings bearing this mutation had normal glucose
tolerance. The p.His137Asp mutation (detected in 1 patient)
altered a moderately conserved amino acid. The activity of hepatic
GCK is regulated by the glucokinase regulatory protein (GKRP).
This would act as an allosteric inhibitor of GCK that specifically
binds to the super-open form. Indeed, mutational analyses [30]
have shown that two GCK fragments, 51–52 and 141–144, are
involved in such interactions. Sequence 141–144 follows the a3
helix that is terminated by His 137. Histidine, by interacting with
the carbonyl of Phe133, is involved in helix capping. Mutation
p.His137Asp introduces a negative charge in the region and, in
Figure 1. Distribution of the GCKmutations. The structure of GCK in
the closed form (PDB code: 1v4s) is shown as cyan and red ribbons that
represent the small and large domain, respectively. Orange ribbons show
the a13 helix. Yellow spheres are the mutation sites. Red and blue circles
indicate clusters of mutations in the large and small domain, respectively.
doi:10.1371/journal.pone.0001870.g001
Figure 2. Structural features of mutations p.Phe123Leu and p.Asp168Ala GCK. The structure of GCK in the closed form (PDB code: 1v4s) is
represented by cyan ribbons. A) Mutation p.Phe123Leu. Phe123 is structured inside the hydrophobic core of the small domain. Yellow sticks
represent hydrophobic residues that constitute the core. Phe123 and Leu123 are represented by red sticks (left and right panel, respectively). B) The
sticks represent residue Thr168 and glucose. The right panels show a close-up view of the glucose-binding cleft for the wild-type (top) and for the
Ala168 mutant (bottom).
doi:10.1371/journal.pone.0001870.g002
Glucokinase Gene Mutations
PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e1870
our simulations, Asp137 does not exert a capping function, but
strongly interacts with Lys104 by making a salt bridge.
Accordingly, p.His137Asp may affect the conformational proper-
ties of fragment 141–144 thereby indirectly influencing the
binding with GKRP. The p.His137Arg mutation has been
described in association with diabetes [31].
The p.Gly162Asp mutation (detected in 1 patient) altered a
highly conserved amino acid. Gly162 is located on the b-sheet that
encloses the small domain hydrophobic core. p.Gly162Asp is one
of the most dramatic mutations we identified because it introduces
a negative residue inside the hydrophobic core. p.Gly162Asp very
probably influences the stability of the core thereby altering the
structure and dynamics of the domain. This scenario is indicative
of functional impairment of the enzyme.
The p.Thr168Ala mutation (detected in 2 related patients)
affected a conserved amino acid. The glucose-binding cleft is
located at the interface between small and large domains. It is
constituted by residues Glu256 and Glu290 from the large
domain, Thr168 and Lys169 from the small domain, and
Asn204 and Asp205 from the interconnecting region. Binding a
glucose molecule requires a precise pattern of H-bonds between
the substrate and GCK. Thr168 binds glucose, therefore the
p.Thr168Ala substitution prevents the formation of the H-bond
and probably perturbs the enzyme’s binding affinity and efficiency.
Mutation p.Thr168Ala has been described in patients affected by
diabetes [32]; it greatly increased Vmax and resulted in a complete
loss of cooperative behaviour associated with glucose binding, the
2 siblings bearing this mutation had normal glucose tolerance and
impaired glycosylated hemoglobin. Glutamate 290 is a highly
conserved residue involved in glucose binding. The p.Glu290X
mutation (detected in 2 unrelated patients) introduces a stop codon
and generates a truncated protein of only 289 amino acids, which
is thus unable to function.
The p.Arg392Ser mutation (detected in 1 patient) alters a
conserved amino acid. Arg392, is located on the a11 helix in the
large domain and is involved in a local H-bond/salt bridge
network. Arg392 is positively charged and makes a salt bridge with
the negative residues Asp42 (a2) and Glu236. The H-bond
network extends to two water molecules and residue Asn240.
These residues, which are far in sequence, are relevant for the
tertiary structure of the domain, in fact serine is unable to replace
the wild-type Arg392 interactions. The p.Arg392Cys mutation was
reported in co-segregation with hyperglycemia in pregnancy [33].
Three patients carried already known GCK mutations:
p.Lys39fsX6, p.Ser453X and p.Glu265Lys. All these mutations
were described in association with hyperglycemia. In particular,
the Ser R Leu mutation at residue 453 was recently found to
reduce GCK activity in a GCK MODY patient [34]. In our GCK
MODY patients, the distribution of mutation sites in the GCK
protein (59%, 33% and 8% in the small domain, large domain and
in the connection region, respectively) differed from the distribu-
tion observed in European Caucasians and in other ethnic groups
(41%, 58% and 1% in the small domain, large domain and in the
connection region, respectively) [5,35]. Consequently, the GCK
small domain may be a hot spot for MODY mutations typical of
Southern Italy. Interestingly, almost all the mutation sites we
describe are in regions involved in structural rearrangements
required for catalysis. This finding supports the notion that
mutations may affect GCK function, which is intimately related to
intermotion domain [7]. Our data confirm the association
between low triglyceride values and GCK mutations and support
a low rate of cardiovascular complications in GCK MODY
diabetes [36]. Interestingly, the two patients (M001 and M013)
with the lowest BMI z scores also had the lowest FPIR values,
which is in line with the finding that, at low levels, insulin does not
exert an anabolic effect [37].
Massa et al. [25] did not find an association between phenotype
and genotype in GCK MODY patients. Two of our unrelated
patients, M001 and M006, who both carried the p.Glu290X
mutation, had a low birth weight but a different diabetic
phenotype as evaluated by OGTT, FPIR tests and triglyceride
level. In contrast, among the three pairs of siblings, each with the
same mutation, two pairs (M022-M023, M028-M029) had almost
identical metabolic phenotypes. In the third pair of siblings (M024-
M025, aged 12 and 5 years respectively), the elder child was
diabetic and the younger had impaired glucose tolerance. In these
two patients, the p.Glu265Lys mutation provoked a dramatic
rearrangement of GCK, which indicates a more severe prognosis.
Thus, both the severity of the GCK mutation and the genetic
background seem to play a relevant role in the GCK MODY
phenotype.
In conclusion, all mutations detected in our diabetic children
from south Italy co-segregated with the diabetic status in one or
two family members of each patient and were not detected during
the screening of 200 normal chromosomes. The new deletion and
missense mutations produced an amino acid substitution at
positions that are well conserved among several species. Finally,
our data show that molecular screening is useful in the diagnosis of
MODY because it allows one to confirm the diagnosis and to
predict the prognosis as well as the clinical course of the patient.
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Figure 3. Structural features of mutations p.His137Asp,
p.Arg392Ser and p.Gly162Asp GCK. The structure of GCK in the
closed form (PDB code:1v4s) is shown as cyan ribbons. A) p.His137Asp.
Loop 141–144, which is involved in GKRP binding, is in red. His137 is at
the end of the a3 helix. His137 is a capping residue of the helix, which is
terminated by the interaction between side chain of His137 and
Phe133. Asp137 (right) is not able to replace His137 interactions but
adds a new interaction with Lys104. B) p.Gly162Asp. Yellow sticks
represent hydrophobic residues that constitute the core. The location of
Gly162 is marked in red (left of the panel). Asp162 is on the right of the
panel. C) p.Arg392Ser. Residues Asp42, Glu236, Asn240 and Arg392 are
represented by yellow sticks. H-bonds are shown in green. The wild-
type enzyme and the p.Arg392Ser mutant are on the left and right of
the panel, respectively.
doi:10.1371/journal.pone.0001870.g003
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